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 ﾠ
One-ﾭ‐sentence	 ﾠsummary:	 ﾠ	 ﾠ	 ﾠ
Gene	 ﾠnetwork	 ﾠreverse	 ﾠengineering	 ﾠrevealed	 ﾠthat	 ﾠHoxA1	 ﾠis	 ﾠan	 ﾠimportant	 ﾠmediator	 ﾠof	 ﾠbreast	 ﾠ
cancer	 ﾠprogression,	 ﾠand	 ﾠsilencing	 ﾠof	 ﾠHoxA1	 ﾠthrough	 ﾠintraductal	 ﾠdelivery	 ﾠof	 ﾠnanoparticle-ﾭ‐
formulated	 ﾠsiRNA	 ﾠin	 ﾠa	 ﾠtransgenic	 ﾠmouse	 ﾠbreast	 ﾠcancer	 ﾠmodel	 ﾠprevented	 ﾠloss	 ﾠof	 ﾠestrogen	 ﾠand	 ﾠ
progesterone	 ﾠreceptor	 ﾠexpression,	 ﾠsuppressed	 ﾠcell	 ﾠproliferation,	 ﾠand	 ﾠreduced	 ﾠmammary	 ﾠ
tumor	 ﾠincidence	 ﾠby	 ﾠ75%.	 ﾠ
	 ﾠ
ABSTRACT	 ﾠ
With	 ﾠ advances	 ﾠ in	 ﾠ screening,	 ﾠ the	 ﾠ incidence	 ﾠ of	 ﾠ detection	 ﾠ of	 ﾠ premalignant	 ﾠ breast	 ﾠ lesions	 ﾠ has	 ﾠ
increased	 ﾠ in	 ﾠ recent	 ﾠ decades;	 ﾠ however,	 ﾠ treatment	 ﾠ options	 ﾠ remain	 ﾠ limited	 ﾠ to	 ﾠ surveillance	 ﾠ or	 ﾠ
surgical	 ﾠremoval	 ﾠby	 ﾠlumpectomy	 ﾠor	 ﾠmastectomy.	 ﾠWe	 ﾠhypothesized	 ﾠthat	 ﾠdisease	 ﾠprogression	 ﾠ
could	 ﾠ be	 ﾠ blocked	 ﾠ by	 ﾠ RNA	 ﾠ interference	 ﾠ (RNAi)	 ﾠ therapy	 ﾠ and	 ﾠ set	 ﾠ out	 ﾠ to	 ﾠ develop	 ﾠ a	 ﾠ targeted	 ﾠ
therapeutic	 ﾠ delivery	 ﾠ strategy.	 ﾠ Using	 ﾠ computational	 ﾠ gene	 ﾠ network	 ﾠ modeling,	 ﾠ we	 ﾠ identified	 ﾠ
HoxA1	 ﾠas	 ﾠa	 ﾠputative	 ﾠdriver	 ﾠof	 ﾠearly	 ﾠmammary	 ﾠcancer	 ﾠprogression	 ﾠin	 ﾠtransgenic	 ﾠC3(1)-ﾭ‐SV40TAg	 ﾠ
mice.	 ﾠSilencing	 ﾠthis	 ﾠgene	 ﾠin	 ﾠcultured	 ﾠmouse	 ﾠor	 ﾠhuman	 ﾠmammary	 ﾠtumor	 ﾠspheroids	 ﾠresulted	 ﾠin	 ﾠ
increased	 ﾠacinar	 ﾠlumen	 ﾠformation,	 ﾠreduced	 ﾠtumor	 ﾠcell	 ﾠproliferation,	 ﾠand	 ﾠrestoration	 ﾠof	 ﾠnormal	 ﾠ
epithelial	 ﾠpolarization.	 ﾠWhen	 ﾠthe	 ﾠHoxA1	 ﾠgene	 ﾠwas	 ﾠsilenced	 ﾠin	 ﾠvivo	 ﾠvia	 ﾠintraductal	 ﾠdelivery	 ﾠof	 ﾠ
nanoparticle-ﾭ‐formulated	 ﾠsmall	 ﾠinterfering	 ﾠRNA	 ﾠ(siRNA)	 ﾠthrough	 ﾠthe	 ﾠnipple	 ﾠof	 ﾠtransgenic	 ﾠmice	 ﾠ
with	 ﾠearly-ﾭ‐stage	 ﾠdisease,	 ﾠmammary	 ﾠepithelial	 ﾠcell	 ﾠproliferate	 ﾠrates	 ﾠwere	 ﾠsuppressed,	 ﾠloss	 ﾠof	 ﾠ
estrogen	 ﾠ and	 ﾠ progesterone	 ﾠ receptor	 ﾠ expression	 ﾠ was	 ﾠ prevented,	 ﾠ and	 ﾠ tumor	 ﾠ incidence	 ﾠ was	 ﾠ	 ﾠ
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 ﾠ
reduced	 ﾠ by	 ﾠ 75%.	 ﾠ 	 ﾠ This	 ﾠ approach	 ﾠ that	 ﾠ leverages	 ﾠ new	 ﾠ advances	 ﾠ in	 ﾠ systems	 ﾠ biology	 ﾠ and	 ﾠ
nanotechnology	 ﾠoffers	 ﾠa	 ﾠnovel	 ﾠnon-ﾭ‐invasive	 ﾠstrategy	 ﾠto	 ﾠblock	 ﾠbreast	 ﾠcancer	 ﾠprogression	 ﾠthrough	 ﾠ
targeted	 ﾠsilencing	 ﾠof	 ﾠcritical	 ﾠgenes	 ﾠdirectly	 ﾠwithin	 ﾠthe	 ﾠmammary	 ﾠepithelium.	 ﾠ	 ﾠ
	 ﾠ
INTRODUCTION	 ﾠ
The	 ﾠmost	 ﾠcommon	 ﾠnon-ﾭ‐invasive	 ﾠlesion	 ﾠof	 ﾠthe	 ﾠbreast	 ﾠis	 ﾠductal	 ﾠcarcinoma	 ﾠin	 ﾠsitu	 ﾠ(DCIS),	 ﾠin	 ﾠwhich	 ﾠ
abnormal	 ﾠductal	 ﾠepithelial	 ﾠcells	 ﾠproliferate	 ﾠinside	 ﾠthe	 ﾠmammary	 ﾠduct	 ﾠbut	 ﾠdo	 ﾠnot	 ﾠpenetrate	 ﾠ
through	 ﾠthe	 ﾠbasement	 ﾠmembrane	 ﾠto	 ﾠinvade	 ﾠadjacent	 ﾠtissue.	 ﾠ	 ﾠIn	 ﾠthe	 ﾠUnited	 ﾠStates,	 ﾠ
approximately	 ﾠ25%	 ﾠof	 ﾠnewly	 ﾠdiagnosed	 ﾠbreast	 ﾠlesions	 ﾠare	 ﾠclassified	 ﾠas	 ﾠDCIS,	 ﾠand	 ﾠmore	 ﾠthan	 ﾠone	 ﾠ
million	 ﾠwomen	 ﾠwill	 ﾠbe	 ﾠliving	 ﾠwith	 ﾠDCIS	 ﾠin	 ﾠthe	 ﾠUnited	 ﾠStates	 ﾠalone	 ﾠby	 ﾠ2020	 ﾠ(1,	 ﾠ2).	 ﾠAtypical	 ﾠductal	 ﾠ
hyperplasia	 ﾠrepresents	 ﾠapproximately	 ﾠ10%	 ﾠof	 ﾠmammographically	 ﾠdetected	 ﾠbreast	 ﾠlesions.	 ﾠ	 ﾠ
These	 ﾠare	 ﾠmarked	 ﾠby	 ﾠthe	 ﾠpresence	 ﾠof	 ﾠabnormal	 ﾠepithelial	 ﾠcells	 ﾠand	 ﾠelevated	 ﾠcell	 ﾠnumbers	 ﾠ
compared	 ﾠwith	 ﾠnormal	 ﾠmammary	 ﾠducts	 ﾠ(3).	 ﾠ	 ﾠAll	 ﾠclasses	 ﾠof	 ﾠearly	 ﾠlesions	 ﾠare	 ﾠhighly	 ﾠ
heterogeneous	 ﾠand,	 ﾠalthough	 ﾠonly	 ﾠa	 ﾠfraction	 ﾠwill	 ﾠprogress	 ﾠto	 ﾠinvasive	 ﾠbreast	 ﾠtumors	 ﾠ(estimates	 ﾠ
range	 ﾠfrom	 ﾠ14	 ﾠto	 ﾠ53%	 ﾠfor	 ﾠDCIS)	 ﾠ(4-ﾭ‐6),	 ﾠthere	 ﾠare	 ﾠcurrently	 ﾠno	 ﾠbiomarkers	 ﾠto	 ﾠaid	 ﾠin	 ﾠidentifying	 ﾠ
which	 ﾠtumors	 ﾠwill	 ﾠbecome	 ﾠinvasive.	 ﾠSurveillance	 ﾠ(so	 ﾠcalled,	 ﾠ“watch-ﾭ‐and-ﾭ‐wait”)	 ﾠmay	 ﾠbe	 ﾠ
recommended	 ﾠfor	 ﾠearlier	 ﾠstages	 ﾠof	 ﾠhyperplasia	 ﾠwith	 ﾠor	 ﾠwithout	 ﾠatypia.	 ﾠ	 ﾠ	 ﾠ
Treatment	 ﾠof	 ﾠpremalignant	 ﾠdisease	 ﾠis	 ﾠtypically	 ﾠaggressive	 ﾠfor	 ﾠDCIS	 ﾠlesions	 ﾠand	 ﾠoptions	 ﾠ
include	 ﾠmastectomy,	 ﾠlumpectomy,	 ﾠand	 ﾠradiation.	 ﾠ	 ﾠAll	 ﾠof	 ﾠthese	 ﾠhave	 ﾠserious	 ﾠsystemic	 ﾠside	 ﾠeffects	 ﾠ
and	 ﾠimpact	 ﾠquality	 ﾠof	 ﾠlife.	 ﾠ	 ﾠSome	 ﾠpatients	 ﾠwith	 ﾠhormone	 ﾠreceptor–positive	 ﾠDCIS	 ﾠwill	 ﾠalso	 ﾠreceive	 ﾠ
five	 ﾠyears	 ﾠof	 ﾠendocrine	 ﾠtherapy,	 ﾠwhich	 ﾠhas	 ﾠbeen	 ﾠshown	 ﾠto	 ﾠreduce	 ﾠrecurrence,	 ﾠalthough	 ﾠno	 ﾠ
survival	 ﾠbenefit	 ﾠhas	 ﾠbeen	 ﾠdemonstrated.	 ﾠ	 ﾠThe	 ﾠside	 ﾠeffects	 ﾠof	 ﾠendocrine	 ﾠtherapy	 ﾠmay	 ﾠbe	 ﾠlife	 ﾠ
threatening	 ﾠand	 ﾠinclude	 ﾠstroke,	 ﾠblood	 ﾠclots,	 ﾠbone	 ﾠloss	 ﾠand	 ﾠelevated	 ﾠrisks	 ﾠof	 ﾠuterine	 ﾠand	 ﾠ	 ﾠ
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endometrial	 ﾠcancers	 ﾠ(7).	 ﾠFor	 ﾠthese	 ﾠreasons,	 ﾠa	 ﾠrecent	 ﾠsurvey	 ﾠof	 ﾠbreast	 ﾠcancer	 ﾠprofessionals	 ﾠ
identified	 ﾠthe	 ﾠneed	 ﾠfor	 ﾠminimally	 ﾠinvasive	 ﾠtherapies	 ﾠthat	 ﾠcan	 ﾠbe	 ﾠselectively	 ﾠtargeted	 ﾠto	 ﾠthe	 ﾠ
ductal	 ﾠepithelium	 ﾠto	 ﾠprevent	 ﾠprogression	 ﾠof	 ﾠpremalignant	 ﾠbreast	 ﾠlesions	 ﾠwithout	 ﾠproducing	 ﾠ
systemic	 ﾠtoxicity	 ﾠas	 ﾠone	 ﾠof	 ﾠthe	 ﾠhighest	 ﾠpriorities	 ﾠof	 ﾠtranslational	 ﾠbreast	 ﾠcancer	 ﾠresearch	 ﾠ(8).	 ﾠ
Small	 ﾠinterfering	 ﾠRNA	 ﾠ(siRNA)	 ﾠhas	 ﾠbeen	 ﾠused	 ﾠas	 ﾠa	 ﾠtherapeutic	 ﾠagent	 ﾠin	 ﾠthe	 ﾠtreatment	 ﾠof	 ﾠa	 ﾠ
variety	 ﾠof	 ﾠtumor	 ﾠtypes	 ﾠin	 ﾠrodent	 ﾠmodels	 ﾠ,	 ﾠincluding	 ﾠhuman	 ﾠmammary	 ﾠtumor	 ﾠxenografts	 ﾠin	 ﾠ
mice(9-ﾭ‐11),	 ﾠand	 ﾠit	 ﾠis	 ﾠwell-ﾭ‐tolerated	 ﾠwith	 ﾠfew	 ﾠadverse	 ﾠside	 ﾠeffects.	 ﾠTherapeutic	 ﾠRNA	 ﾠinterference	 ﾠ
(RNAi)	 ﾠis	 ﾠalso	 ﾠcurrently	 ﾠbeing	 ﾠtested	 ﾠin	 ﾠhuman	 ﾠclinical	 ﾠtrials	 ﾠin	 ﾠpatients	 ﾠwith	 ﾠliver	 ﾠcancer,	 ﾠ
metastatic	 ﾠliver	 ﾠdisease,	 ﾠpancreatic	 ﾠductal	 ﾠadenocarcinoma,	 ﾠadvanced	 ﾠcolon	 ﾠcancer	 ﾠand	 ﾠfamilial	 ﾠ
adenomatous	 ﾠpolyposis	 ﾠ(FAP)	 ﾠwhich	 ﾠleads	 ﾠto	 ﾠcolon	 ﾠtumorigenesis	 ﾠ(12).	 ﾠRNAi	 ﾠbased	 ﾠapproaches	 ﾠ
are	 ﾠinteresting	 ﾠbecause	 ﾠthey	 ﾠoffer	 ﾠthe	 ﾠpossibility	 ﾠfor	 ﾠa	 ﾠmore	 ﾠpersonalized	 ﾠtherapy	 ﾠin	 ﾠthat	 ﾠthe	 ﾠ
same	 ﾠtechnology	 ﾠand	 ﾠapproach	 ﾠcan	 ﾠbe	 ﾠadapted	 ﾠto	 ﾠa	 ﾠvariety	 ﾠof	 ﾠtumor-ﾭ‐specific	 ﾠgene	 ﾠtargets.	 ﾠIn	 ﾠ
addition,	 ﾠRNAi	 ﾠis	 ﾠuseful	 ﾠfor	 ﾠsilencing	 ﾠundruggable	 ﾠtargets	 ﾠthat	 ﾠare	 ﾠnot	 ﾠamenable	 ﾠto	 ﾠtraditional	 ﾠ
small	 ﾠmolecule–	 ﾠor	 ﾠantibody-ﾭ‐based	 ﾠinhibition	 ﾠ(13-ﾭ‐15).	 ﾠ	 ﾠNevertheless,	 ﾠdevelopment	 ﾠof	 ﾠRNAi-ﾭ‐
based	 ﾠcancer	 ﾠtherapeutics	 ﾠhas	 ﾠbeen	 ﾠhampered	 ﾠby	 ﾠtwo	 ﾠmajor	 ﾠobstacles:	 ﾠ1)	 ﾠidentification	 ﾠof	 ﾠ
appropriate	 ﾠtarget	 ﾠgenes	 ﾠthat	 ﾠare	 ﾠcausally	 ﾠinvolved	 ﾠin	 ﾠcancer	 ﾠdevelopment,	 ﾠand	 ﾠ2)	 ﾠselection	 ﾠof	 ﾠ
an	 ﾠeffective	 ﾠdelivery	 ﾠmethod	 ﾠwith	 ﾠminimal	 ﾠsystemic	 ﾠside	 ﾠeffects.	 ﾠ	 ﾠ	 ﾠ
Here,	 ﾠwe	 ﾠaddressed	 ﾠthe	 ﾠfirst	 ﾠchallenge	 ﾠthrough	 ﾠgene	 ﾠnetwork	 ﾠinference—a	 ﾠ
computational	 ﾠbiology	 ﾠapproach	 ﾠthat	 ﾠevaluates	 ﾠgene	 ﾠexpression	 ﾠchanges	 ﾠin	 ﾠcontext	 ﾠof	 ﾠthe	 ﾠ
entire	 ﾠgene	 ﾠregulatory	 ﾠnetwork	 ﾠ(GRN).	 ﾠThrough	 ﾠthis	 ﾠanalysis,	 ﾠwe	 ﾠidentified	 ﾠthe	 ﾠHoxA1	 ﾠgene	 ﾠas	 ﾠa	 ﾠ
critical	 ﾠmediator	 ﾠof	 ﾠmammary	 ﾠtumor	 ﾠprogression.	 ﾠ	 ﾠ	 ﾠWith	 ﾠincreasing	 ﾠavailability	 ﾠof	 ﾠgenome-ﾭ‐wide	 ﾠ
characterization	 ﾠof	 ﾠclinical	 ﾠsamples,	 ﾠwe	 ﾠenvision	 ﾠthe	 ﾠbroad	 ﾠapplication	 ﾠof	 ﾠthis	 ﾠapproach	 ﾠto	 ﾠ	 ﾠ
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multiple	 ﾠtypes	 ﾠof	 ﾠpremalignant	 ﾠlesions,	 ﾠin	 ﾠthe	 ﾠbreast	 ﾠand	 ﾠother	 ﾠorgans.	 ﾠ	 ﾠTo	 ﾠvalidate	 ﾠthe	 ﾠ
importance	 ﾠof	 ﾠthis	 ﾠgene	 ﾠfor	 ﾠbreast	 ﾠcancer	 ﾠprogression	 ﾠand	 ﾠto	 ﾠaddress	 ﾠthe	 ﾠsecond	 ﾠchallenge,	 ﾠwe	 ﾠ
delivered	 ﾠHoxA1	 ﾠsiRNA	 ﾠinto	 ﾠmammary	 ﾠepithelial	 ﾠcells	 ﾠin	 ﾠvivo	 ﾠusing	 ﾠlipidoid	 ﾠnanoparticles,	 ﾠwhich	 ﾠ
have	 ﾠbeen	 ﾠshown	 ﾠto	 ﾠfacilitate	 ﾠinteraction	 ﾠwith	 ﾠthe	 ﾠcell	 ﾠmembrane	 ﾠand	 ﾠendosomal	 ﾠescape	 ﾠin	 ﾠ
other	 ﾠtissues,	 ﾠincluding	 ﾠan	 ﾠovarian	 ﾠtumor	 ﾠmodel	 ﾠin	 ﾠmice	 ﾠ(16).	 ﾠIn	 ﾠcontrast	 ﾠto	 ﾠearlier	 ﾠstudies	 ﾠin	 ﾠ
which	 ﾠlipidoid-ﾭ‐formulated	 ﾠsiRNA	 ﾠwas	 ﾠinjected	 ﾠintratumorally,	 ﾠwe	 ﾠdelivered	 ﾠthe	 ﾠnanoparticles	 ﾠto	 ﾠ
premalignant	 ﾠlesions	 ﾠwithin	 ﾠthe	 ﾠlining	 ﾠepithelium	 ﾠof	 ﾠintact	 ﾠmammary	 ﾠglands	 ﾠof	 ﾠvirgin	 ﾠtransgenic	 ﾠ
mice	 ﾠby	 ﾠdirect	 ﾠinjection	 ﾠthrough	 ﾠthe	 ﾠnipple.	 ﾠ	 ﾠLocal	 ﾠdelivery	 ﾠis	 ﾠnon-ﾭ‐invasive	 ﾠand	 ﾠavoids	 ﾠthe	 ﾠuptake	 ﾠ
and	 ﾠaccumulation	 ﾠof	 ﾠnanoparticles	 ﾠin	 ﾠthe	 ﾠliver—an	 ﾠissue	 ﾠthat	 ﾠhas	 ﾠproven	 ﾠchallenging	 ﾠin	 ﾠsystemic	 ﾠ
administration	 ﾠ(17).	 ﾠ	 ﾠ
HoxA1	 ﾠsilencing	 ﾠwas	 ﾠtested	 ﾠin	 ﾠhuman	 ﾠmammary	 ﾠspheroids	 ﾠas	 ﾠwell	 ﾠas	 ﾠin	 ﾠa	 ﾠtransgenic	 ﾠmouse	 ﾠ
model	 ﾠof	 ﾠmammary	 ﾠtumorigenesis.	 ﾠ	 ﾠThe	 ﾠFVB	 ﾠC3(1)	 ﾠSV40TAg	 ﾠtransgenic	 ﾠmouse	 ﾠwas	 ﾠchosen	 ﾠas	 ﾠa	 ﾠ
relevant	 ﾠmodel	 ﾠof	 ﾠhuman	 ﾠbreast	 ﾠcancer	 ﾠbecause:	 ﾠ1)	 ﾠtumors	 ﾠform	 ﾠspontaneously	 ﾠin	 ﾠthe	 ﾠcorrect	 ﾠ
tissue	 ﾠmicroenvironment,	 ﾠ2)	 ﾠtumor	 ﾠonset	 ﾠand	 ﾠformation	 ﾠare	 ﾠslow,	 ﾠoccurring	 ﾠover	 ﾠa	 ﾠperiod	 ﾠof	 ﾠ4-ﾭ‐5	 ﾠ
months,	 ﾠ3)	 ﾠlesions	 ﾠrobustly	 ﾠprogress	 ﾠthrough	 ﾠall	 ﾠof	 ﾠthe	 ﾠtypical	 ﾠstages	 ﾠof	 ﾠbreast	 ﾠtumorigenesis	 ﾠ
seen	 ﾠin	 ﾠhumans,	 ﾠincluding	 ﾠhyperplasia	 ﾠductal	 ﾠcarcinoma	 ﾠin	 ﾠsitu	 ﾠ(DCIS),	 ﾠand	 ﾠlocally	 ﾠinvasive	 ﾠ
carcinomas	 ﾠthat	 ﾠcan	 ﾠmetastasizd	 ﾠto	 ﾠthe	 ﾠlung	 ﾠand	 ﾠliver,	 ﾠ4)	 ﾠthe	 ﾠimmune	 ﾠsystem	 ﾠremains	 ﾠintact.	 ﾠ	 ﾠ
and	 ﾠ5)	 ﾠtumor	 ﾠonset	 ﾠdoes	 ﾠnot	 ﾠrequire	 ﾠexogenous	 ﾠhormone	 ﾠintervention	 ﾠor	 ﾠpregnancy	 ﾠis	 ﾠrequired	 ﾠ
in	 ﾠother	 ﾠtransgenic	 ﾠbreast	 ﾠcancer	 ﾠmodels	 ﾠ(18,	 ﾠ19).	 ﾠ	 ﾠ	 ﾠ
	 ﾠ
RESULTS	 ﾠ
Putative	 ﾠtarget	 ﾠidentification	 ﾠby	 ﾠcomputational	 ﾠgene	 ﾠnetwork	 ﾠinference	 ﾠ	 ﾠ	 ﾠ
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To	 ﾠidentify	 ﾠcandidate	 ﾠgene	 ﾠtargets	 ﾠwith	 ﾠa	 ﾠhigh	 ﾠlikelihood	 ﾠof	 ﾠdriving	 ﾠtumor	 ﾠprogression	 ﾠin	 ﾠthe	 ﾠ
transgenic	 ﾠmouse	 ﾠFVB	 ﾠC3(1)-ﾭ‐SV40TAg	 ﾠmodel,	 ﾠwe	 ﾠconstructed	 ﾠmodels	 ﾠof	 ﾠGRN	 ﾠconnectivity	 ﾠwith	 ﾠ
the	 ﾠMode-ﾭ‐of-ﾭ‐action	 ﾠby	 ﾠNetwork	 ﾠIdentification	 ﾠ(MNI)	 ﾠtool	 ﾠ(20,	 ﾠ21).	 ﾠA	 ﾠdetailed	 ﾠdescription	 ﾠof	 ﾠthe	 ﾠ
MNI	 ﾠalgorithm	 ﾠmay	 ﾠbe	 ﾠfound	 ﾠin	 ﾠSupplementary	 ﾠMethods.	 ﾠ	 ﾠIn	 ﾠsummary,	 ﾠthe	 ﾠMNI	 ﾠtool	 ﾠwas	 ﾠfirst	 ﾠ
trained	 ﾠon	 ﾠ3,000	 ﾠgene	 ﾠmicroarray	 ﾠdatasets	 ﾠfrom	 ﾠvarious	 ﾠmouse	 ﾠtissues	 ﾠand	 ﾠorgans	 ﾠunder	 ﾠ
diverse	 ﾠconditions	 ﾠto	 ﾠdevelop	 ﾠa	 ﾠbasal	 ﾠGRN	 ﾠconnectivity	 ﾠmodel⊯a	 ﾠdirected	 ﾠgraph	 ﾠthat	 ﾠrelates	 ﾠ
the	 ﾠconcentration	 ﾠof	 ﾠeach	 ﾠgene	 ﾠtranscript	 ﾠto	 ﾠthat	 ﾠof	 ﾠevery	 ﾠother	 ﾠtranscript	 ﾠacross	 ﾠthe	 ﾠgenome	 ﾠ
(Fig.	 ﾠ1;	 ﾠfig.	 ﾠS1).	 ﾠ	 ﾠGenes	 ﾠare	 ﾠdeemed	 ﾠto	 ﾠbe	 ﾠconnected	 ﾠin	 ﾠthis	 ﾠnetwork	 ﾠif	 ﾠthe	 ﾠactivity	 ﾠof	 ﾠone	 ﾠgene	 ﾠ
influences	 ﾠthe	 ﾠtranscriptional	 ﾠstate	 ﾠof	 ﾠthe	 ﾠother,	 ﾠregardless	 ﾠof	 ﾠwhether	 ﾠthe	 ﾠeffect	 ﾠoccurs	 ﾠat	 ﾠ
transcriptional	 ﾠor	 ﾠpost-ﾭ‐transcriptional	 ﾠlevels	 ﾠand	 ﾠindependently	 ﾠof	 ﾠthe	 ﾠtype	 ﾠor	 ﾠdirectionality	 ﾠof	 ﾠ
the	 ﾠinteraction.	 ﾠ	 ﾠHierarchical	 ﾠclustering	 ﾠ(by	 ﾠEuclidean	 ﾠdistance	 ﾠwith	 ﾠcomplete	 ﾠlinkage	 ﾠperformed	 ﾠ
with	 ﾠthe	 ﾠZ-ﾭ‐score–normalized	 ﾠexpression	 ﾠvalue)	 ﾠrevealed	 ﾠthat	 ﾠsamples	 ﾠclustered	 ﾠbased	 ﾠon	 ﾠ
disease	 ﾠprogression	 ﾠ(fig.	 ﾠS1A).	 ﾠExpression	 ﾠprofiles	 ﾠof	 ﾠtransgenic	 ﾠglands	 ﾠfrom	 ﾠearly	 ﾠstages	 ﾠof	 ﾠ
cancer	 ﾠprogression	 ﾠ(<16	 ﾠweeks)	 ﾠwere	 ﾠmost	 ﾠsimilar,	 ﾠwhereas	 ﾠthe	 ﾠprofile	 ﾠof	 ﾠthe	 ﾠ20-ﾭ‐week	 ﾠglands	 ﾠ
that	 ﾠcontained	 ﾠfulminant	 ﾠcancers	 ﾠwas	 ﾠclearly	 ﾠdistinct	 ﾠ(Pearson	 ﾠcorrelation	 ﾠcoefficient	 ﾠ>	 ﾠ0.99	 ﾠat	 ﾠ
20	 ﾠweeks	 ﾠversus	 ﾠ~0.92	 ﾠat	 ﾠearlier	 ﾠtimes;	 ﾠfig.	 ﾠS1B	 ﾠand	 ﾠfig.	 ﾠS1C).	 ﾠ
The	 ﾠtrained	 ﾠGRN	 ﾠmodel	 ﾠwas	 ﾠthen	 ﾠtested	 ﾠwith	 ﾠtransgenic	 ﾠand	 ﾠwild	 ﾠtype	 ﾠmammary	 ﾠgland	 ﾠ
transcriptome	 ﾠdata	 ﾠto	 ﾠidentify	 ﾠthe	 ﾠearliest	 ﾠchanges	 ﾠthat	 ﾠrewire	 ﾠthe	 ﾠGRN	 ﾠduring	 ﾠtumorigenesis.	 ﾠ
In	 ﾠfemale	 ﾠtransgenic	 ﾠC3(1)-ﾭ‐SV40TAg	 ﾠmice,	 ﾠbreast	 ﾠtumor	 ﾠformation	 ﾠprogresses	 ﾠin	 ﾠa	 ﾠhighly	 ﾠ
reproducible	 ﾠmanner,	 ﾠwith	 ﾠhyperplasia	 ﾠfirst	 ﾠappearing	 ﾠat	 ﾠ~	 ﾠ12	 ﾠweeks	 ﾠof	 ﾠage,	 ﾠDCIS-ﾭ‐like	 ﾠlesions	 ﾠat	 ﾠ
~	 ﾠ16	 ﾠweeks,	 ﾠand	 ﾠinvasive	 ﾠcarcinomas	 ﾠat	 ﾠ20	 ﾠweeks	 ﾠ(Fig.	 ﾠ2A)	 ﾠ(19).	 ﾠ	 ﾠ	 ﾠTo	 ﾠfocus	 ﾠon	 ﾠearly	 ﾠevents	 ﾠin	 ﾠ
tumorigenesis,	 ﾠwhole	 ﾠgenome	 ﾠtranscriptome	 ﾠprofiles	 ﾠwere	 ﾠobtained	 ﾠfor	 ﾠmammary	 ﾠglands	 ﾠ	 ﾠ
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isolated	 ﾠfrom	 ﾠ8	 ﾠweek-ﾭ‐old	 ﾠtransgenic	 ﾠmice	 ﾠwhen	 ﾠthe	 ﾠtransgene	 ﾠis	 ﾠhighly	 ﾠexpressed,	 ﾠbut	 ﾠthe	 ﾠ
glands	 ﾠremain	 ﾠhistologically	 ﾠnormal.	 ﾠ	 ﾠCandidate	 ﾠtranscription	 ﾠfactors	 ﾠwere	 ﾠranked	 ﾠby	 ﾠtwo-ﾭ‐tailed	 ﾠ
p-ﾭ‐value	 ﾠand	 ﾠthe	 ﾠHoxA1	 ﾠgene	 ﾠemerged	 ﾠas	 ﾠthe	 ﾠmost	 ﾠsignificant	 ﾠpotential	 ﾠkey	 ﾠmediator	 ﾠof	 ﾠearly	 ﾠ
cancer	 ﾠprogression	 ﾠ(p	 ﾠ=	 ﾠ0.0005)	 ﾠ(Fig.	 ﾠ1).	 ﾠWe	 ﾠfocused	 ﾠon	 ﾠHoxA1	 ﾠbecause	 ﾠpast	 ﾠwork	 ﾠin	 ﾠhuman	 ﾠ
tissues	 ﾠalso	 ﾠsuggested	 ﾠthat	 ﾠit	 ﾠmight	 ﾠplay	 ﾠan	 ﾠimportant	 ﾠrole	 ﾠin	 ﾠbreast	 ﾠcancer	 ﾠdevelopment	 ﾠ(22-ﾭ‐
24).	 ﾠ
	 ﾠ
Validation	 ﾠof	 ﾠtargets	 ﾠin	 ﾠthree-ﾭ‐dimensional	 ﾠmouse	 ﾠmammary	 ﾠepithelial	 ﾠcell	 ﾠspheroids	 ﾠ	 ﾠ
To	 ﾠassess	 ﾠthe	 ﾠfunctional	 ﾠrelevance	 ﾠof	 ﾠHoxA1	 ﾠto	 ﾠbreast	 ﾠcancer	 ﾠbiology,	 ﾠwe	 ﾠthen	 ﾠexplored	 ﾠ
whether	 ﾠdown-ﾭ‐regulating	 ﾠits	 ﾠexpression	 ﾠwould	 ﾠalter	 ﾠthe	 ﾠgrowth	 ﾠor	 ﾠdifferentiation	 ﾠof	 ﾠcultured	 ﾠ
mammary	 ﾠepithelial	 ﾠtumor	 ﾠcells	 ﾠthat	 ﾠwere	 ﾠoriginally	 ﾠisolated	 ﾠfrom	 ﾠprimary	 ﾠ(M6)	 ﾠor	 ﾠmetastatic	 ﾠ
(M6C)	 ﾠtumors	 ﾠin	 ﾠthe	 ﾠsame	 ﾠtransgenic	 ﾠC3(1)-ﾭ‐SV40-ﾭ‐Tag	 ﾠmice	 ﾠ(25).	 ﾠ	 ﾠHoxA1	 ﾠwas	 ﾠsilenced	 ﾠwith	 ﾠsiRNA	 ﾠ
in	 ﾠM6	 ﾠand	 ﾠM6C	 ﾠcells,	 ﾠor	 ﾠin	 ﾠnormal	 ﾠmouse	 ﾠEph4	 ﾠmammary	 ﾠepithelial	 ﾠcells,	 ﾠwhich	 ﾠwere	 ﾠcultured	 ﾠ
within	 ﾠextracellular	 ﾠmatrix	 ﾠ(ECM)	 ﾠgels	 ﾠcomposed	 ﾠof	 ﾠMatrigel	 ﾠand	 ﾠtype	 ﾠI	 ﾠcollagen.	 ﾠMore	 ﾠthan	 ﾠ
75%	 ﾠof	 ﾠthe	 ﾠnormal	 ﾠEph4	 ﾠmammary	 ﾠcells	 ﾠformed	 ﾠwell-ﾭ‐differentiated,	 ﾠhollow	 ﾠacinar	 ﾠspheroids	 ﾠ
lined	 ﾠby	 ﾠa	 ﾠpolarized	 ﾠepithelium	 ﾠwith	 ﾠa	 ﾠcentral	 ﾠlumen	 ﾠ(Fig.	 ﾠ2B).	 ﾠ	 ﾠ	 ﾠ
These	 ﾠnormal	 ﾠmammary	 ﾠcells	 ﾠwere	 ﾠalso	 ﾠhighly	 ﾠpolarized	 ﾠas	 ﾠindicated	 ﾠby	 ﾠthe	 ﾠ
accumulation	 ﾠof	 ﾠa	 ﾠcircumferential	 ﾠbasement	 ﾠmembrane	 ﾠcontaining	 ﾠa	 ﾠlinear	 ﾠdistribution	 ﾠof	 ﾠ
laminin-ﾭ‐5	 ﾠalong	 ﾠtheir	 ﾠbasal	 ﾠmembranes,	 ﾠand	 ﾠa	 ﾠpreferentially	 ﾠapical	 ﾠdistribution	 ﾠof	 ﾠGM130	 ﾠafter	 ﾠ
2	 ﾠweeks	 ﾠof	 ﾠculture,	 ﾠwhich	 ﾠmimics	 ﾠnormal	 ﾠpolarized	 ﾠmammary	 ﾠepithelial	 ﾠarchitecture	 ﾠin	 ﾠvivo	 ﾠ(Fig.	 ﾠ
2,	 ﾠA	 ﾠand	 ﾠB).	 ﾠIn	 ﾠcontrast,	 ﾠM6	 ﾠand	 ﾠM6C	 ﾠtumor	 ﾠcells	 ﾠfailed	 ﾠto	 ﾠform	 ﾠhollow	 ﾠlumens	 ﾠand	 ﾠinstead	 ﾠgrew	 ﾠ
as	 ﾠdisorganized	 ﾠspheroids	 ﾠfilled	 ﾠwith	 ﾠcells	 ﾠin	 ﾠvitro	 ﾠ(Fig.	 ﾠ2,	 ﾠB	 ﾠand	 ﾠC),	 ﾠmuch	 ﾠas	 ﾠthey	 ﾠdo	 ﾠwhen	 ﾠthey	 ﾠ	 ﾠ
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form	 ﾠsolid	 ﾠtumors	 ﾠduring	 ﾠlater	 ﾠstages	 ﾠof	 ﾠcancer	 ﾠprogression	 ﾠin	 ﾠvivo	 ﾠ(Fig.	 ﾠ2A).	 ﾠAs	 ﾠexpected	 ﾠfrom	 ﾠ
their	 ﾠin	 ﾠvivo	 ﾠbehavior,	 ﾠM6	 ﾠand	 ﾠM6C	 ﾠcells	 ﾠalso	 ﾠdid	 ﾠnot	 ﾠform	 ﾠa	 ﾠpolarized	 ﾠepithelium	 ﾠor	 ﾠaccumulate	 ﾠ
a	 ﾠlinear	 ﾠbasement	 ﾠmembrane	 ﾠalong	 ﾠtheir	 ﾠperiphery	 ﾠ(Fig.	 ﾠ2B).	 ﾠ	 ﾠ	 ﾠ
Gene	 ﾠsilencing	 ﾠusing	 ﾠHoxA1	 ﾠsiRNA	 ﾠ(siHoxA1)	 ﾠ(fig.	 ﾠS2A)	 ﾠinduced	 ﾠboth	 ﾠM6	 ﾠand	 ﾠM6C	 ﾠcancer	 ﾠ
cells	 ﾠto	 ﾠreorganize	 ﾠinto	 ﾠhollow	 ﾠacinar	 ﾠstructures	 ﾠlined	 ﾠby	 ﾠa	 ﾠpolarized	 ﾠepithelium,	 ﾠwith	 ﾠ
restoration	 ﾠof	 ﾠboth	 ﾠapical	 ﾠGM130	 ﾠstaining	 ﾠand	 ﾠa	 ﾠcontinuous,	 ﾠlaminin-ﾭ‐5–containing	 ﾠbasement	 ﾠ
membrane	 ﾠat	 ﾠtheir	 ﾠbasal	 ﾠcell	 ﾠsurface	 ﾠ(Fig.	 ﾠ2,	 ﾠB	 ﾠand	 ﾠC).	 ﾠThus,	 ﾠsilencing	 ﾠof	 ﾠa	 ﾠsingle	 ﾠgene	 ﾠidentified	 ﾠ
by	 ﾠthe	 ﾠMNI	 ﾠalgorithm	 ﾠ⊯	 ﾠHoxA1	 ﾠ⊯	 ﾠresulted	 ﾠin	 ﾠbreast	 ﾠcancer	 ﾠdifferentiation	 ﾠincluding	 ﾠ
reconstitution	 ﾠof	 ﾠthe	 ﾠnormal	 ﾠtissue	 ﾠarchitecture	 ﾠof	 ﾠwild	 ﾠtype	 ﾠmammary	 ﾠgland	 ﾠthat	 ﾠis	 ﾠgradually	 ﾠ
lost	 ﾠin	 ﾠtransgenic	 ﾠglands	 ﾠduring	 ﾠdisease	 ﾠprogression	 ﾠ(Fig.	 ﾠ2B).	 ﾠ	 ﾠSpheroid	 ﾠdifferentiation	 ﾠinduced	 ﾠ
by	 ﾠgene	 ﾠsilencing	 ﾠwas	 ﾠalso	 ﾠaccompanied	 ﾠby	 ﾠa	 ﾠsignificant	 ﾠreduction	 ﾠin	 ﾠthe	 ﾠpercentage	 ﾠof	 ﾠ
proliferating	 ﾠtumor	 ﾠcells	 ﾠin	 ﾠvitro	 ﾠ(Fig.	 ﾠ2D),	 ﾠwhile	 ﾠthe	 ﾠoverall	 ﾠcell	 ﾠnumber	 ﾠper	 ﾠspheroid	 ﾠremained	 ﾠ
the	 ﾠsame.	 ﾠ	 ﾠThis	 ﾠis	 ﾠconsistent	 ﾠwith	 ﾠthe	 ﾠfinding	 ﾠthat	 ﾠa	 ﾠconcomitant	 ﾠincrease	 ﾠin	 ﾠtumor	 ﾠcell	 ﾠ
apoptosis	 ﾠwas	 ﾠobserved	 ﾠwithin	 ﾠthe	 ﾠnewly	 ﾠformed	 ﾠacinar	 ﾠlumens	 ﾠ(Fig.	 ﾠ2E).	 ﾠTreatment	 ﾠof	 ﾠM6	 ﾠand	 ﾠ
M6C	 ﾠcells	 ﾠwith	 ﾠsiHoxA1	 ﾠreduced	 ﾠDNA	 ﾠsynthesis	 ﾠby	 ﾠmore	 ﾠthan	 ﾠ50%	 ﾠand	 ﾠ32%,	 ﾠrespectively,	 ﾠand	 ﾠ
apoptosis	 ﾠincreased	 ﾠby	 ﾠapproximately	 ﾠ2-ﾭ‐fold	 ﾠ(~16.5%	 ﾠTUNEL-ﾭ‐positive	 ﾠcells	 ﾠin	 ﾠsiHoxA1-ﾭ‐treated	 ﾠ
cells	 ﾠvs.	 ﾠ8.5%	 ﾠin	 ﾠcontrol	 ﾠM6	 ﾠand	 ﾠM6C	 ﾠcells).	 ﾠ	 ﾠ
	 ﾠ
Silencing	 ﾠHoxA1	 ﾠin	 ﾠhuman	 ﾠbreast	 ﾠcancer	 ﾠ	 ﾠ
To	 ﾠexamine	 ﾠthe	 ﾠrelevance	 ﾠof	 ﾠHoxA1	 ﾠfor	 ﾠhuman	 ﾠbreast	 ﾠcancer,	 ﾠwe	 ﾠperformed	 ﾠdifferential	 ﾠ
expression	 ﾠanalysis	 ﾠusing	 ﾠthe	 ﾠOncomine	 ﾠcompendium	 ﾠof	 ﾠcancer	 ﾠtranscriptome	 ﾠprofiles	 ﾠobtained	 ﾠ
from	 ﾠpatient	 ﾠtumor	 ﾠsamples.	 ﾠ	 ﾠHuman	 ﾠpatient	 ﾠdata	 ﾠfrom	 ﾠten	 ﾠpreviously	 ﾠpublished	 ﾠgene	 ﾠ	 ﾠ
	 ﾠ 8	 ﾠ
expression	 ﾠanalyses,	 ﾠeach	 ﾠconsisting	 ﾠof	 ﾠ22	 ﾠto	 ﾠ150	 ﾠsamples	 ﾠrepresenting	 ﾠhealthy	 ﾠbreast	 ﾠtissue	 ﾠ
and	 ﾠtumors	 ﾠ(26-ﾭ‐31)	 ﾠrevealed	 ﾠthat	 ﾠHoxA1	 ﾠwas	 ﾠover-ﾭ‐expressed	 ﾠby	 ﾠgreater	 ﾠthan	 ﾠ2-ﾭ‐fold	 ﾠin	 ﾠhuman	 ﾠ
breast	 ﾠlesions	 ﾠ(Fig.	 ﾠ3A),	 ﾠwhich	 ﾠsupports	 ﾠthe	 ﾠrelevance	 ﾠof	 ﾠthe	 ﾠpresent	 ﾠresults	 ﾠfor	 ﾠhuman	 ﾠdisease.	 ﾠ	 ﾠ
To	 ﾠmore	 ﾠdirectly	 ﾠexplore	 ﾠthis	 ﾠpossibility,	 ﾠwe	 ﾠthen	 ﾠtested	 ﾠwhether	 ﾠsilencing	 ﾠof	 ﾠits	 ﾠexpression	 ﾠ
using	 ﾠsiRNA	 ﾠwould	 ﾠalter	 ﾠthe	 ﾠproliferation	 ﾠor	 ﾠdifferentiation	 ﾠof	 ﾠhuman	 ﾠMDA-ﾭ‐MB-ﾭ‐468	 ﾠand	 ﾠ
HCC1937	 ﾠbreast	 ﾠtumor	 ﾠcells	 ﾠwhen	 ﾠgrown	 ﾠwithin	 ﾠthe	 ﾠsame	 ﾠECM	 ﾠgels	 ﾠused	 ﾠfor	 ﾠthe	 ﾠmouse	 ﾠ
mammary	 ﾠtumor	 ﾠ3D	 ﾠcultures.	 ﾠUpon	 ﾠsilencing	 ﾠHoxA1,	 ﾠwe	 ﾠobserved	 ﾠa	 ﾠmajor	 ﾠincrease	 ﾠin	 ﾠthe	 ﾠability	 ﾠ
of	 ﾠboth	 ﾠhuman	 ﾠbreast	 ﾠtumor	 ﾠcell	 ﾠlines	 ﾠto	 ﾠorganize	 ﾠinto	 ﾠspheroids	 ﾠcontaining	 ﾠhollow	 ﾠcentral	 ﾠ
lumens	 ﾠunder	 ﾠthese	 ﾠ3D	 ﾠgel	 ﾠculture	 ﾠconditions	 ﾠ(Fig.	 ﾠ3B),	 ﾠwith	 ﾠsiHoxA1-ﾭ‐treated	 ﾠMDA-ﾭ‐MB-ﾭ‐468	 ﾠcells	 ﾠ
and	 ﾠHCC1937	 ﾠcells	 ﾠexhibiting	 ﾠapproximately	 ﾠ6-ﾭ‐fold	 ﾠand	 ﾠ>	 ﾠ2-ﾭ‐fold	 ﾠincreases	 ﾠrelative	 ﾠto	 ﾠspheroids	 ﾠ
treated	 ﾠwith	 ﾠnon-ﾭ‐targeting	 ﾠcontrol	 ﾠsiRNA,	 ﾠrespectively	 ﾠ(Fig.	 ﾠ3C).	 ﾠ	 ﾠBetween	 ﾠ30	 ﾠand	 ﾠ38%	 ﾠof	 ﾠ
spheroids	 ﾠformed	 ﾠhollow	 ﾠlumens	 ﾠin	 ﾠthe	 ﾠsiHoxA1-ﾭ‐treated	 ﾠhuman	 ﾠbreast	 ﾠcancer	 ﾠcell	 ﾠcultures,	 ﾠ
compared	 ﾠwith	 ﾠ~50%	 ﾠof	 ﾠspheroids	 ﾠformed	 ﾠby	 ﾠnormal	 ﾠhuman	 ﾠmammary	 ﾠepithelial	 ﾠMCF10A	 ﾠcells	 ﾠ
(Fig.	 ﾠ3,	 ﾠB	 ﾠand	 ﾠC).	 ﾠ	 ﾠAnalysis	 ﾠof	 ﾠDNA	 ﾠsynthesis	 ﾠunder	 ﾠthese	 ﾠculture	 ﾠconditions	 ﾠrevealed	 ﾠthat	 ﾠthe	 ﾠ
growth	 ﾠof	 ﾠthe	 ﾠMDA-ﾭ‐MB-ﾭ‐468	 ﾠcells	 ﾠand	 ﾠHCC1937	 ﾠcells	 ﾠwere	 ﾠreduced	 ﾠby	 ﾠ60	 ﾠand	 ﾠ50%,	 ﾠrespectively,	 ﾠ
upon	 ﾠsilencing	 ﾠHoxA1	 ﾠ(Fig.3D).	 ﾠ	 ﾠSimilar	 ﾠresults	 ﾠwere	 ﾠalso	 ﾠobserved	 ﾠin	 ﾠhuman	 ﾠbreast	 ﾠcancer	 ﾠcells	 ﾠ
cultured	 ﾠin	 ﾠ2D	 ﾠon	 ﾠconventional	 ﾠcell	 ﾠculture	 ﾠplastic	 ﾠ(fig.	 ﾠS2,A	 ﾠ	 ﾠand	 ﾠB).	 ﾠThus,	 ﾠsilencing	 ﾠHoxA1	 ﾠ
suppressed	 ﾠgrowth	 ﾠand	 ﾠrestored	 ﾠdifferentiation,	 ﾠas	 ﾠmeasured	 ﾠby	 ﾠnormal	 ﾠacinar	 ﾠmorphology	 ﾠand	 ﾠ
lumen	 ﾠformation,	 ﾠto	 ﾠtwo	 ﾠhuman	 ﾠbreast	 ﾠtumor	 ﾠcell	 ﾠlines.	 ﾠ
	 ﾠ
In	 ﾠvivo	 ﾠHoxA1	 ﾠsilencing	 ﾠwithin	 ﾠmammary	 ﾠgland	 ﾠby	 ﾠintraductal	 ﾠdelivery	 ﾠof	 ﾠsiRNA-ﾭ‐lipidoid	 ﾠ
nanoparticles	 ﾠ	 ﾠ	 ﾠ
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To	 ﾠexplore	 ﾠwhether	 ﾠHoxA1	 ﾠrepresents	 ﾠa	 ﾠfeasible	 ﾠtarget	 ﾠfor	 ﾠtreating	 ﾠthe	 ﾠearly	 ﾠstages	 ﾠof	 ﾠbreast	 ﾠ
cancer	 ﾠprogression,	 ﾠHoxA1	 ﾠand	 ﾠcontrol,	 ﾠnon-ﾭ‐targeting	 ﾠsiRNAs	 ﾠ(siNTs)	 ﾠwere	 ﾠformulated	 ﾠwith	 ﾠ
lipidoid	 ﾠnanoparticles	 ﾠ(16,	 ﾠ32).	 ﾠ	 ﾠThese	 ﾠparticles	 ﾠwere	 ﾠdelivered	 ﾠintraductally	 ﾠvia	 ﾠinjection	 ﾠ
through	 ﾠthe	 ﾠnipple	 ﾠto	 ﾠreach	 ﾠthe	 ﾠtransformed	 ﾠmammary	 ﾠepithelial	 ﾠcells	 ﾠthat	 ﾠgive	 ﾠrise	 ﾠto	 ﾠearly	 ﾠ
localized	 ﾠlesions	 ﾠwithin	 ﾠthe	 ﾠlining	 ﾠductal	 ﾠepithelium.	 ﾠ	 ﾠInjection	 ﾠof	 ﾠa	 ﾠfluorescently	 ﾠtagged	 ﾠcontrol	 ﾠ
siRNA	 ﾠformulated	 ﾠwith	 ﾠlipidoid	 ﾠconfirmed	 ﾠthat	 ﾠa	 ﾠvolume	 ﾠof	 ﾠ20	 ﾠµl	 ﾠof	 ﾠsiRNA-ﾭ‐nanoparticle	 ﾠsolution	 ﾠ
filled	 ﾠthe	 ﾠintact	 ﾠmammary	 ﾠtree	 ﾠand	 ﾠthat	 ﾠthe	 ﾠnipple	 ﾠand	 ﾠmammary	 ﾠducts	 ﾠremained	 ﾠintact	 ﾠ
throughout	 ﾠthe	 ﾠtreatment	 ﾠ(Fig.	 ﾠ4A;	 ﾠfig.	 ﾠS3A).	 ﾠIn	 ﾠhigh-ﾭ‐magnification	 ﾠconfocal	 ﾠimages	 ﾠof	 ﾠinjected	 ﾠ
mammary	 ﾠducts,	 ﾠfluorescent	 ﾠnanoparticles	 ﾠwere	 ﾠobserved	 ﾠwithin	 ﾠmammary	 ﾠepithelial	 ﾠcells	 ﾠat	 ﾠ
48	 ﾠh	 ﾠand	 ﾠ1	 ﾠweek	 ﾠpost-ﾭ‐injection,	 ﾠand	 ﾠthey	 ﾠwere	 ﾠnot	 ﾠobserved	 ﾠin	 ﾠthe	 ﾠstromal	 ﾠcells	 ﾠthat	 ﾠsurround	 ﾠ
the	 ﾠepithelium	 ﾠ(Fig.	 ﾠ4B).	 ﾠ	 ﾠNo	 ﾠfluorescent	 ﾠparticles	 ﾠwere	 ﾠobserved	 ﾠin	 ﾠthe	 ﾠliver,	 ﾠspleen,	 ﾠkidney,	 ﾠ
heart,	 ﾠlung,	 ﾠor	 ﾠperipheral	 ﾠblood	 ﾠat	 ﾠ48	 ﾠh,	 ﾠ72	 ﾠh,	 ﾠor	 ﾠ1	 ﾠweek	 ﾠpost-ﾭ‐injection.	 ﾠ	 ﾠ	 ﾠ
To	 ﾠdetermine	 ﾠthe	 ﾠpotential	 ﾠtherapeutic	 ﾠvalue	 ﾠof	 ﾠthis	 ﾠapproach	 ﾠin	 ﾠvivo,	 ﾠvirgin	 ﾠadult	 ﾠ
female	 ﾠtransgenic	 ﾠmice	 ﾠwere	 ﾠinjected	 ﾠwith	 ﾠsiHoxA1	 ﾠor	 ﾠnon-ﾭ‐targeting	 ﾠcontrol	 ﾠsiRNA	 ﾠbiweekly	 ﾠfor	 ﾠ
9	 ﾠweeks	 ﾠbeginning	 ﾠat	 ﾠ12	 ﾠweeks	 ﾠof	 ﾠage	 ﾠ.	 ﾠGene	 ﾠsilencing	 ﾠwas	 ﾠconfirmed	 ﾠby	 ﾠimmunoblotting	 ﾠof	 ﾠ
protein	 ﾠisolated	 ﾠfrom	 ﾠmammary	 ﾠglands	 ﾠafter	 ﾠthe	 ﾠ9
th	 ﾠweek	 ﾠof	 ﾠtreatment	 ﾠ(fig.	 ﾠS3B).	 ﾠWhile	 ﾠ100%	 ﾠof	 ﾠ
control	 ﾠtransgenic	 ﾠmice	 ﾠ(n	 ﾠ=	 ﾠ5)	 ﾠor	 ﾠmice	 ﾠtreated	 ﾠwith	 ﾠnon-ﾭ‐targeting	 ﾠsiRNA	 ﾠ(n	 ﾠ=	 ﾠ10)	 ﾠdeveloped	 ﾠ
macroscopic	 ﾠtumors	 ﾠby	 ﾠ21	 ﾠweeks	 ﾠof	 ﾠage,	 ﾠonly	 ﾠ25%	 ﾠof	 ﾠmice	 ﾠtreated	 ﾠwith	 ﾠintraductal	 ﾠinjection	 ﾠof	 ﾠ
siHoxA1	 ﾠ(n	 ﾠ=	 ﾠ8)	 ﾠexhibited	 ﾠtumor	 ﾠformation	 ﾠ(p	 ﾠ<	 ﾠ0.0001,	 ﾠlog	 ﾠrank	 ﾠtest)	 ﾠ(Fig.	 ﾠ4C).	 ﾠTumor	 ﾠonset	 ﾠin	 ﾠ
those	 ﾠmice	 ﾠwas	 ﾠdelayed	 ﾠby	 ﾠapproximately	 ﾠ3	 ﾠweeks,	 ﾠas	 ﾠdetected	 ﾠby	 ﾠweekly	 ﾠultrasound	 ﾠ
monitoring	 ﾠ(Fig.	 ﾠ4D).	 ﾠ	 ﾠImmunohistological	 ﾠcharacterization	 ﾠof	 ﾠthe	 ﾠsiHoxA1-ﾭ‐treated	 ﾠmammary	 ﾠ
glands	 ﾠrevealed	 ﾠthe	 ﾠpresence	 ﾠof	 ﾠhyperplasia	 ﾠand	 ﾠductal	 ﾠfilling	 ﾠat	 ﾠ21	 ﾠweeks	 ﾠ(Fig.	 ﾠ4E);	 ﾠhowever,	 ﾠ	 ﾠ
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these	 ﾠlesions	 ﾠdid	 ﾠnot	 ﾠprogress	 ﾠto	 ﾠinvasive	 ﾠmacroscopic	 ﾠtumors	 ﾠin	 ﾠglands	 ﾠtreated	 ﾠwith	 ﾠsiHoxA1	 ﾠ
(Fig.	 ﾠ4,	 ﾠC	 ﾠto	 ﾠE).	 ﾠCell	 ﾠproliferation	 ﾠalso	 ﾠwas	 ﾠlower	 ﾠin	 ﾠglands	 ﾠinjected	 ﾠwith	 ﾠsiHoxA1	 ﾠin	 ﾠvivo	 ﾠ
compared	 ﾠwith	 ﾠcontrols,	 ﾠas	 ﾠmeasured	 ﾠby	 ﾠPCNA	 ﾠ(Fig.	 ﾠ3F),	 ﾠbut	 ﾠthere	 ﾠwas	 ﾠno	 ﾠsignificant	 ﾠchange	 ﾠin	 ﾠ
the	 ﾠlevels	 ﾠof	 ﾠapoptosis	 ﾠ(P	 ﾠ>	 ﾠ0.05,	 ﾠFisher’s	 ﾠt	 ﾠtest)	 ﾠ(fig.	 ﾠS3C),	 ﾠ	 ﾠsuggesting	 ﾠthat	 ﾠHoxA1	 ﾠinhibition	 ﾠ
acted	 ﾠby	 ﾠincreasing	 ﾠ(or	 ﾠpreventing	 ﾠloss	 ﾠof)	 ﾠcell	 ﾠdifferentiation,	 ﾠrather	 ﾠthan	 ﾠby	 ﾠinducing	 ﾠ
mammary	 ﾠtumor	 ﾠapoptosis.	 ﾠ	 ﾠ	 ﾠ
Mammary	 ﾠtumorigenesis	 ﾠin	 ﾠC3(1)-ﾭ‐SV40TAg	 ﾠtransgenic	 ﾠglands	 ﾠis	 ﾠalso	 ﾠmarked	 ﾠby	 ﾠ
progressive	 ﾠloss	 ﾠof	 ﾠexpression	 ﾠof	 ﾠhormone	 ﾠreceptors,	 ﾠmost	 ﾠnotably	 ﾠthe	 ﾠestrogen	 ﾠreceptor	 ﾠ(ER)	 ﾠ
and	 ﾠprogesterone	 ﾠreceptor	 ﾠ(PR).	 ﾠ	 ﾠThis	 ﾠis	 ﾠa	 ﾠcommon	 ﾠcharacteristic	 ﾠof	 ﾠthe	 ﾠmost	 ﾠhighly	 ﾠaggressive	 ﾠ
forms	 ﾠof	 ﾠbreast	 ﾠcancer	 ﾠin	 ﾠhumans	 ﾠas	 ﾠwell.	 ﾠ	 ﾠInterestingly,	 ﾠwhile	 ﾠonly	 ﾠ4.7%	 ﾠand	 ﾠ5.9%	 ﾠof	 ﾠcells	 ﾠwere	 ﾠ
ER+	 ﾠin	 ﾠuntreated	 ﾠand	 ﾠsiNT-ﾭ‐treated	 ﾠglands,	 ﾠrespectively,	 ﾠat	 ﾠ21	 ﾠweeks	 ﾠof	 ﾠage,	 ﾠsiHoxA1-ﾭ‐treated	 ﾠ
glands	 ﾠcontinued	 ﾠto	 ﾠexpress	 ﾠER	 ﾠat	 ﾠhigh	 ﾠlevels,	 ﾠwith	 ﾠ18.4%	 ﾠof	 ﾠcells	 ﾠstaining	 ﾠpositive	 ﾠfor	 ﾠER	 ﾠ(p	 ﾠ<	 ﾠ10
-ﾭ‐
7	 ﾠby	 ﾠPearson’s	 ﾠchi-ﾭ‐square	 ﾠtest)	 ﾠ(Fig.	 ﾠ4,	 ﾠE	 ﾠand	 ﾠG).	 ﾠ	 ﾠA	 ﾠsimilar	 ﾠresponse	 ﾠwas	 ﾠobserved	 ﾠfor	 ﾠPR,	 ﾠwith	 ﾠ
15.7%	 ﾠof	 ﾠPR+	 ﾠcells	 ﾠin	 ﾠsiHoxA1-ﾭ‐treated	 ﾠglands	 ﾠversus	 ﾠonly	 ﾠ5.9	 ﾠ%	 ﾠand	 ﾠ7.9%	 ﾠof	 ﾠin	 ﾠuntreated	 ﾠand	 ﾠ
siNT-ﾭ‐treated	 ﾠglands	 ﾠ(p	 ﾠ<	 ﾠ10
-ﾭ‐7	 ﾠby	 ﾠPearson’s	 ﾠchi-ﾭ‐square	 ﾠtest)	 ﾠ(Fig.	 ﾠ4,	 ﾠE	 ﾠand	 ﾠH).	 ﾠ	 ﾠ
FVB	 ﾠC3(1)-ﾭ‐SV40TAg	 ﾠmice	 ﾠreceiving	 ﾠintraductal	 ﾠinjections	 ﾠof	 ﾠsiRNA-ﾭ‐lipidoid	 ﾠnanoparticles	 ﾠ
were	 ﾠalso	 ﾠmonitored	 ﾠclosely	 ﾠfor	 ﾠsigns	 ﾠof	 ﾠlocal	 ﾠtissue	 ﾠdamage,	 ﾠtoxicity	 ﾠor	 ﾠsystemic	 ﾠside	 ﾠeffects.	 ﾠ	 ﾠ
No	 ﾠweight	 ﾠloss	 ﾠwas	 ﾠobserved	 ﾠin	 ﾠthe	 ﾠsiHoxA1-ﾭ‐	 ﾠor	 ﾠsiNT-ﾭ‐treated	 ﾠpopulations	 ﾠ(fig.	 ﾠS4A).	 ﾠWe	 ﾠalso	 ﾠ
failed	 ﾠto	 ﾠdetect	 ﾠan	 ﾠinflammatory	 ﾠresponse,	 ﾠeither	 ﾠwhen	 ﾠsystemic	 ﾠresponses	 ﾠwere	 ﾠanalyzed	 ﾠby	 ﾠ
measuring	 ﾠspleen	 ﾠsize	 ﾠor	 ﾠby	 ﾠquantitating	 ﾠchanges	 ﾠin	 ﾠinterleukin-ﾭ‐6	 ﾠand	 ﾠinterferon-ﾭ‐γ	 ﾠcytokine	 ﾠ
levels	 ﾠin	 ﾠresponse	 ﾠto	 ﾠadministration	 ﾠof	 ﾠsiHoxA1-ﾭ‐	 ﾠor	 ﾠsiNT-ﾭ‐containing	 ﾠnanoparticles	 ﾠ(P	 ﾠ>	 ﾠ0.05,	 ﾠchi-ﾭ‐
square	 ﾠtest)	 ﾠ(fig.	 ﾠS4,	 ﾠB-ﾭ‐D).	 ﾠ	 ﾠHence,	 ﾠmammary	 ﾠcancer	 ﾠprogression	 ﾠwas	 ﾠsuppressed	 ﾠin	 ﾠthis	 ﾠrobust	 ﾠ	 ﾠ
	 ﾠ 11	 ﾠ
transgenic	 ﾠmodel	 ﾠwithout	 ﾠproducing	 ﾠdetectable	 ﾠgeneralized	 ﾠtoxicities	 ﾠby	 ﾠlocalized	 ﾠdelivery	 ﾠof	 ﾠ
siHoxA1.	 ﾠ
	 ﾠ
HoxA1	 ﾠsilencing	 ﾠdownregulates	 ﾠMAPK	 ﾠsignaling	 ﾠ
Activation	 ﾠof	 ﾠthe	 ﾠMAP	 ﾠkinase	 ﾠpathway	 ﾠregulating	 ﾠcell	 ﾠproliferation	 ﾠand	 ﾠsurvival	 ﾠis	 ﾠa	 ﾠfrequent	 ﾠ
event	 ﾠin	 ﾠtumorigenesis,	 ﾠand	 ﾠmodulation	 ﾠof	 ﾠthe	 ﾠp44/42	 ﾠMAP	 ﾠkinase	 ﾠsignaling	 ﾠpathway	 ﾠhas	 ﾠ
previously	 ﾠbeen	 ﾠshown	 ﾠto	 ﾠcontribute	 ﾠto	 ﾠthe	 ﾠmechanism	 ﾠby	 ﾠwhich	 ﾠHoxA1	 ﾠmediates	 ﾠoncogenic	 ﾠ
transformation	 ﾠand	 ﾠanchorage-ﾭ‐independent	 ﾠgrowth	 ﾠin	 ﾠcultured	 ﾠhuman	 ﾠmammary	 ﾠtumor	 ﾠcells	 ﾠ
(33).	 ﾠ	 ﾠWe	 ﾠtherefore	 ﾠinvestigated	 ﾠthe	 ﾠresponse	 ﾠof	 ﾠp44/42	 ﾠsignaling	 ﾠto	 ﾠlocal	 ﾠHoxA1	 ﾠsilencing	 ﾠin	 ﾠ
mouse	 ﾠmammary	 ﾠglands	 ﾠin	 ﾠvivo.	 ﾠ	 ﾠGene	 ﾠexpression	 ﾠanalysis	 ﾠof	 ﾠtransgenic	 ﾠmammary	 ﾠglands	 ﾠ
revealed	 ﾠalterations	 ﾠin	 ﾠexpression	 ﾠof	 ﾠ13	 ﾠcore	 ﾠgenes	 ﾠinvolved	 ﾠin	 ﾠthe	 ﾠp44/42	 ﾠMAPK	 ﾠsignaling	 ﾠ
pathway	 ﾠas	 ﾠthe	 ﾠdisease	 ﾠprogressed	 ﾠfrom	 ﾠearly	 ﾠto	 ﾠlate	 ﾠstages	 ﾠ(Fig.	 ﾠ5A).	 ﾠIntraductal	 ﾠdelivery	 ﾠof	 ﾠ
siHoxA1	 ﾠreduced	 ﾠexpression	 ﾠof	 ﾠKras,	 ﾠErk1/2,	 ﾠSrc,	 ﾠGrb2,	 ﾠand	 ﾠIer3	 ﾠ(Fig.	 ﾠ5B)	 ﾠin	 ﾠthe	 ﾠtransgenic	 ﾠ
mammary	 ﾠgland.	 ﾠ	 ﾠ	 ﾠ
	 ﾠ
DISCUSSION	 ﾠ
These	 ﾠdata	 ﾠshow	 ﾠthat	 ﾠa	 ﾠGRN	 ﾠcomputational	 ﾠapproach	 ﾠdesigned	 ﾠto	 ﾠdefine	 ﾠGRN	 ﾠconnectivity	 ﾠcan	 ﾠ
be	 ﾠused	 ﾠto	 ﾠsuccessfully	 ﾠidentify	 ﾠgenes	 ﾠthat	 ﾠare	 ﾠphysiologically	 ﾠrelevant	 ﾠto	 ﾠhuman	 ﾠbreast	 ﾠtumor	 ﾠ
progression,	 ﾠand	 ﾠthat	 ﾠcan	 ﾠserve	 ﾠas	 ﾠpotential	 ﾠtherapeutic	 ﾠtargets	 ﾠwith	 ﾠRNAi.	 ﾠIntraductal	 ﾠdelivery	 ﾠ
of	 ﾠsiRNA	 ﾠencapsulated	 ﾠin	 ﾠlipidoid	 ﾠnanoparticles	 ﾠenabled	 ﾠlocalization	 ﾠto	 ﾠthe	 ﾠrelevant	 ﾠcells	 ﾠlining	 ﾠ
the	 ﾠmammary	 ﾠducts	 ﾠthat	 ﾠgive	 ﾠrise	 ﾠto	 ﾠthe	 ﾠmajority	 ﾠof	 ﾠinvasive	 ﾠbreast	 ﾠtumors.	 ﾠ	 ﾠTo	 ﾠour	 ﾠknowledge,	 ﾠ	 ﾠ
	 ﾠ 12	 ﾠ
this	 ﾠis	 ﾠthe	 ﾠfirst	 ﾠexample	 ﾠof	 ﾠminimally	 ﾠinvasive	 ﾠlocal	 ﾠdelivery	 ﾠof	 ﾠRNAi-ﾭ‐based	 ﾠtherapeutic	 ﾠagents	 ﾠ
through	 ﾠthe	 ﾠnipple.	 ﾠ	 ﾠ
This	 ﾠapproach	 ﾠcan	 ﾠbe	 ﾠgeneralized	 ﾠto	 ﾠtarget	 ﾠany	 ﾠcandidate	 ﾠgene,	 ﾠallowing	 ﾠthe	 ﾠtreatment	 ﾠ
of	 ﾠbreast	 ﾠlesions	 ﾠin	 ﾠa	 ﾠtumor-ﾭ‐specific	 ﾠand	 ﾠpatient-ﾭ‐specific	 ﾠmanner.	 ﾠ	 ﾠFor	 ﾠexample,	 ﾠit	 ﾠmay	 ﾠbe	 ﾠ
possible	 ﾠto	 ﾠpersonalize	 ﾠsiRNA	 ﾠtreatments	 ﾠfor	 ﾠpatients	 ﾠwith	 ﾠknown	 ﾠgene	 ﾠmutations..	 ﾠ	 ﾠIn	 ﾠthis	 ﾠ
study,	 ﾠwe	 ﾠdetermined	 ﾠthat	 ﾠHoxA1	 ﾠwas	 ﾠa	 ﾠcritical	 ﾠtranscriptional	 ﾠregulator	 ﾠduring	 ﾠearly	 ﾠstages	 ﾠof	 ﾠ	 ﾠ
mammary	 ﾠtumorigenesis;	 ﾠthus,	 ﾠwe	 ﾠtailored	 ﾠRNAi	 ﾠtherapy	 ﾠto	 ﾠthis	 ﾠtarget.	 ﾠHox	 ﾠgenes	 ﾠact	 ﾠas	 ﾠmaster	 ﾠ
regulators	 ﾠof	 ﾠdevelopment	 ﾠin	 ﾠthe	 ﾠembryo	 ﾠand	 ﾠthey	 ﾠare	 ﾠexpressed	 ﾠin	 ﾠa	 ﾠtightly	 ﾠregulated	 ﾠ
spatiotemporal	 ﾠfashion.	 ﾠ	 ﾠIn	 ﾠhumans,	 ﾠHoxA1	 ﾠplays	 ﾠa	 ﾠcritical	 ﾠrole	 ﾠin	 ﾠearly	 ﾠembryonic	 ﾠdevelopment	 ﾠ
and	 ﾠis	 ﾠcritical	 ﾠin	 ﾠhindbrain	 ﾠsegmentation,	 ﾠskull	 ﾠmorphogenesis,	 ﾠand	 ﾠinner	 ﾠear	 ﾠorganogenesis	 ﾠ(34).	 ﾠ	 ﾠ
Alterations	 ﾠin	 ﾠHox	 ﾠgenes	 ﾠalso	 ﾠhave	 ﾠbeen	 ﾠassociated	 ﾠwith	 ﾠa	 ﾠvariety	 ﾠof	 ﾠhuman	 ﾠcancers,	 ﾠincluding	 ﾠ
breast	 ﾠ(22,	 ﾠ35),	 ﾠskin	 ﾠ(36),	 ﾠlung	 ﾠ(37),	 ﾠprostate	 ﾠ(38),	 ﾠand	 ﾠhematopoietic	 ﾠtumors	 ﾠ(39).	 ﾠ	 ﾠHoxA1	 ﾠis	 ﾠnot	 ﾠ
expressed	 ﾠin	 ﾠadult	 ﾠhuman	 ﾠmammary	 ﾠgland,	 ﾠbut	 ﾠseveral	 ﾠprevious	 ﾠstudies	 ﾠhave	 ﾠrevealed	 ﾠ
upregulation	 ﾠin	 ﾠmammary	 ﾠcarcinomas	 ﾠ(22,	 ﾠ23,	 ﾠ40,	 ﾠ41).	 ﾠAlthough	 ﾠadditional	 ﾠstudies	 ﾠwill	 ﾠbe	 ﾠ
required	 ﾠto	 ﾠclarify	 ﾠthe	 ﾠmechanism	 ﾠby	 ﾠwhich	 ﾠHoxA1	 ﾠcontributes	 ﾠto	 ﾠbreast	 ﾠtumor	 ﾠformation	 ﾠin	 ﾠ
humans,	 ﾠprevious	 ﾠwork	 ﾠhas	 ﾠshown	 ﾠthat	 ﾠover-ﾭ‐expression	 ﾠof	 ﾠHoxA1	 ﾠin	 ﾠnormal	 ﾠhuman	 ﾠmammary	 ﾠ
epithelial	 ﾠcells	 ﾠis	 ﾠsufficient	 ﾠto	 ﾠinitiate	 ﾠoncogenic	 ﾠtransformation	 ﾠ(24).	 ﾠ	 ﾠFurthermore,	 ﾠwe	 ﾠ
demonstrate	 ﾠhere	 ﾠthat	 ﾠsilencing	 ﾠHoxA1	 ﾠsuppresses	 ﾠgrowth	 ﾠand	 ﾠinduces	 ﾠdifferentiation	 ﾠof	 ﾠ
human	 ﾠbreast	 ﾠcancer	 ﾠspheroids	 ﾠand	 ﾠthat	 ﾠsuppression	 ﾠof	 ﾠthis	 ﾠgene	 ﾠin	 ﾠthe	 ﾠearly	 ﾠstages	 ﾠof	 ﾠthe	 ﾠ
disease	 ﾠis	 ﾠassociated	 ﾠwith	 ﾠreduced	 ﾠMAPK	 ﾠsignaling	 ﾠin	 ﾠmice,	 ﾠsuggesting	 ﾠthat	 ﾠit	 ﾠmay	 ﾠalso	 ﾠbe	 ﾠa	 ﾠ
relevant	 ﾠtarget	 ﾠin	 ﾠhuman	 ﾠtumors	 ﾠthat	 ﾠrespond	 ﾠto	 ﾠMEK	 ﾠinhibitors.	 ﾠ	 ﾠ	 ﾠ	 ﾠ
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The	 ﾠpromise	 ﾠof	 ﾠless-ﾭ‐invasive,	 ﾠintraductal	 ﾠalternatives	 ﾠfor	 ﾠhuman	 ﾠbreast	 ﾠcancer	 ﾠpatients	 ﾠ
has	 ﾠbeen	 ﾠwidely	 ﾠdiscussed	 ﾠin	 ﾠrecent	 ﾠyears,	 ﾠand	 ﾠsmall	 ﾠpilot	 ﾠstudies	 ﾠhave	 ﾠdemonstrated	 ﾠthe	 ﾠ
feasibility	 ﾠof	 ﾠcannulating	 ﾠdiseased	 ﾠducts	 ﾠin	 ﾠhumans	 ﾠ(42)	 ﾠfor	 ﾠthe	 ﾠdelivery	 ﾠof	 ﾠchemotherapeutic	 ﾠ
agents	 ﾠto	 ﾠspecific	 ﾠducts	 ﾠ(43).	 ﾠConventional	 ﾠchemotherapeutic	 ﾠagents,	 ﾠsuch	 ﾠas	 ﾠ5-ﾭ‐FU,	 ﾠcarboplatin,	 ﾠ
and	 ﾠpegylated	 ﾠliposomal	 ﾠdoxorubicin,	 ﾠhave	 ﾠalso	 ﾠbeen	 ﾠshown	 ﾠto	 ﾠbe	 ﾠeffective	 ﾠwhen	 ﾠinjected	 ﾠ
intraductally	 ﾠin	 ﾠrodent	 ﾠmodels	 ﾠof	 ﾠchemically	 ﾠinduced	 ﾠcarcinogenesis	 ﾠ(44,	 ﾠ45).	 ﾠ	 ﾠHowever,	 ﾠlong-ﾭ‐
term	 ﾠfollow	 ﾠup	 ﾠ(>	 ﾠ30	 ﾠweeks)	 ﾠrevealed	 ﾠthat	 ﾠintraductal	 ﾠdelivery	 ﾠof	 ﾠthis	 ﾠform	 ﾠof	 ﾠdoxorubicin	 ﾠalso	 ﾠ
induced	 ﾠformation	 ﾠof	 ﾠmalignant	 ﾠmammary	 ﾠtumors	 ﾠin	 ﾠnormal	 ﾠFVB/N	 ﾠmice	 ﾠ(46).	 ﾠ	 ﾠOur	 ﾠresults	 ﾠshow	 ﾠ
that	 ﾠRNAi-ﾭ‐based	 ﾠtherapies	 ﾠcan	 ﾠbe	 ﾠsimilarly	 ﾠdelivered	 ﾠintraductally	 ﾠin	 ﾠa	 ﾠtransgenic	 ﾠmouse	 ﾠ
mammary	 ﾠcancer	 ﾠmodel,	 ﾠwhich	 ﾠboth	 ﾠprovides	 ﾠa	 ﾠmore	 ﾠrelevant	 ﾠanimal	 ﾠmodel	 ﾠfor	 ﾠbreast	 ﾠcancer	 ﾠ
progression	 ﾠand	 ﾠopens	 ﾠup	 ﾠthe	 ﾠpossibility	 ﾠfor	 ﾠstreamlined	 ﾠdevelopment	 ﾠof	 ﾠthis	 ﾠclass	 ﾠof	 ﾠnon-ﾭ‐
cytotoxic	 ﾠsiRNA-ﾭ‐based	 ﾠagents	 ﾠas	 ﾠa	 ﾠnew	 ﾠminimally-ﾭ‐invasive,	 ﾠlocalized	 ﾠtreatment	 ﾠoption.	 ﾠ
All	 ﾠuntreated	 ﾠSV40	 ﾠTAg	 ﾠanimals	 ﾠdeveloped	 ﾠtumors	 ﾠby	 ﾠ21	 ﾠweeks	 ﾠof	 ﾠage	 ﾠand	 ﾠhence,	 ﾠthey	 ﾠ
needed	 ﾠto	 ﾠbe	 ﾠsacrificed	 ﾠat	 ﾠthis	 ﾠtime	 ﾠaccording	 ﾠto	 ﾠhumane	 ﾠanimal	 ﾠcare	 ﾠprocedures.	 ﾠ	 ﾠTherefore,	 ﾠ
the	 ﾠ21-ﾭ‐week	 ﾠendpoint	 ﾠwas	 ﾠchosen	 ﾠto	 ﾠpermit	 ﾠcomparison	 ﾠof	 ﾠthe	 ﾠtumor	 ﾠburden	 ﾠin	 ﾠuntreated	 ﾠand	 ﾠ
siRNA	 ﾠHoxA1	 ﾠtreated	 ﾠgroups.	 ﾠ	 ﾠSo	 ﾠwhile	 ﾠthis	 ﾠstudy	 ﾠdemonstrated	 ﾠsafety	 ﾠand	 ﾠefficacy	 ﾠthroughout	 ﾠ
the	 ﾠ21-ﾭ‐week	 ﾠstudy	 ﾠperiod,	 ﾠwe	 ﾠcan	 ﾠnot	 ﾠcomment	 ﾠon	 ﾠthe	 ﾠlong-ﾭ‐term	 ﾠeffects	 ﾠof	 ﾠRNAi	 ﾠtherapy.	 ﾠ	 ﾠIn	 ﾠ
any	 ﾠcase,	 ﾠadditional	 ﾠstudies	 ﾠwill	 ﾠbe	 ﾠneeded	 ﾠto	 ﾠcharacterize	 ﾠthe	 ﾠpharmacokinetics,	 ﾠlong-ﾭ‐term	 ﾠ
safety,	 ﾠand	 ﾠlong-ﾭ‐term	 ﾠdosing	 ﾠand	 ﾠefficacy	 ﾠof	 ﾠintraductally	 ﾠadministered	 ﾠRNAi	 ﾠtherapeutics	 ﾠ
before	 ﾠthis	 ﾠtherapeutic	 ﾠstrategy	 ﾠis	 ﾠexplored	 ﾠfor	 ﾠclinical	 ﾠuse.	 ﾠUnlike	 ﾠmice,	 ﾠhuman	 ﾠbreasts	 ﾠcontain	 ﾠ
multiple	 ﾠductal	 ﾠsystems	 ﾠwith	 ﾠseparate	 ﾠopenings	 ﾠon	 ﾠthe	 ﾠnipple.	 ﾠ	 ﾠThus,	 ﾠa	 ﾠlarge	 ﾠanimal	 ﾠmodel	 ﾠwith	 ﾠ
similar	 ﾠmammary	 ﾠgland	 ﾠanatomy,	 ﾠsuch	 ﾠas	 ﾠrabbit,	 ﾠmay	 ﾠprovide	 ﾠadditional	 ﾠinsight.	 ﾠ	 ﾠIt	 ﾠis	 ﾠimportant	 ﾠ	 ﾠ
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to	 ﾠnote,	 ﾠhowever,	 ﾠthat	 ﾠthe	 ﾠdiameter	 ﾠand	 ﾠvolume	 ﾠof	 ﾠthe	 ﾠhuman	 ﾠbreast	 ﾠducts	 ﾠare	 ﾠlarger	 ﾠthan	 ﾠ
mouse,	 ﾠbut	 ﾠstill	 ﾠlined	 ﾠby	 ﾠa	 ﾠsingle	 ﾠlayer	 ﾠof	 ﾠepithelial	 ﾠcells;	 ﾠthis	 ﾠmay	 ﾠallow	 ﾠadministration	 ﾠof	 ﾠhigher	 ﾠ
doses	 ﾠor	 ﾠuse	 ﾠof	 ﾠless	 ﾠfrequent	 ﾠdosing.	 ﾠ	 ﾠIn	 ﾠthe	 ﾠend,	 ﾠappropriate	 ﾠdosing	 ﾠin	 ﾠhumans	 ﾠwould	 ﾠhave	 ﾠbe	 ﾠ
determined	 ﾠand	 ﾠoptimized	 ﾠin	 ﾠPhase	 ﾠI	 ﾠclinical	 ﾠtrials.	 ﾠ	 ﾠ	 ﾠ
If	 ﾠthis	 ﾠtherapeutic	 ﾠstrategy	 ﾠis	 ﾠfound	 ﾠto	 ﾠbe	 ﾠuseful	 ﾠin	 ﾠhumans	 ﾠin	 ﾠthe	 ﾠfuture,	 ﾠthe	 ﾠtherapeutic	 ﾠ
RNAi	 ﾠcould	 ﾠbe	 ﾠadministered	 ﾠin	 ﾠa	 ﾠprophylactic	 ﾠcapacity	 ﾠto	 ﾠhigh-ﾭ‐risk	 ﾠpatients,	 ﾠprior	 ﾠto	 ﾠthe	 ﾠ
detection	 ﾠof	 ﾠDCIS	 ﾠor	 ﾠbreast	 ﾠlesions.	 ﾠ	 ﾠAlternatively,	 ﾠit	 ﾠcould	 ﾠbe	 ﾠadministered	 ﾠwith	 ﾠchemotherapy	 ﾠ
to	 ﾠwomen	 ﾠwho	 ﾠhave	 ﾠtumors	 ﾠremoved	 ﾠand	 ﾠwho	 ﾠwould	 ﾠnormally	 ﾠreceive	 ﾠchemotherapy	 ﾠ(or	 ﾠ
radiation	 ﾠtherapy)	 ﾠto	 ﾠprevent	 ﾠprogression	 ﾠof	 ﾠremaining	 ﾠsmall	 ﾠundetected	 ﾠlesions.	 ﾠThe	 ﾠfeasibility,	 ﾠ
absence	 ﾠof	 ﾠside	 ﾠeffects	 ﾠover	 ﾠseveral	 ﾠmonths,	 ﾠand	 ﾠthe	 ﾠoverall	 ﾠprevention	 ﾠof	 ﾠtumor	 ﾠprogression	 ﾠ
observed	 ﾠin	 ﾠthis	 ﾠstudy	 ﾠsupport	 ﾠthe	 ﾠfurther	 ﾠinvestigation	 ﾠof	 ﾠintraductal	 ﾠdelivery	 ﾠof	 ﾠpatient-ﾭ‐
specific	 ﾠsiRNA	 ﾠtherapy	 ﾠfor	 ﾠbreast	 ﾠcancer	 ﾠprevention	 ﾠand	 ﾠtreatment.	 ﾠ	 ﾠHowever,	 ﾠsafety	 ﾠstudies	 ﾠin	 ﾠ




At	 ﾠ21	 ﾠweeks	 ﾠof	 ﾠage,	 ﾠFVB	 ﾠC3(1)	 ﾠSV40	 ﾠTag	 ﾠanimals	 ﾠtypically	 ﾠhave	 ﾠmammary	 ﾠtumors	 ﾠgreater	 ﾠthan	 ﾠ
10%	 ﾠof	 ﾠbody	 ﾠweight	 ﾠand	 ﾠmust	 ﾠbe	 ﾠsacrificed	 ﾠaccording	 ﾠto	 ﾠanimal	 ﾠcare	 ﾠprotocols.	 ﾠ	 ﾠWe	 ﾠtherefore	 ﾠ
chose	 ﾠ21	 ﾠweeks	 ﾠas	 ﾠan	 ﾠendpoint	 ﾠto	 ﾠallow	 ﾠcomparison	 ﾠof	 ﾠthe	 ﾠtumor	 ﾠburden	 ﾠin	 ﾠtreated	 ﾠanimals	 ﾠto	 ﾠ
the	 ﾠcontrol	 ﾠgroup	 ﾠ(without	 ﾠsiHoxA1	 ﾠtreatment).	 ﾠAnimals	 ﾠwere	 ﾠassigned	 ﾠrandomly	 ﾠto	 ﾠ
experimental	 ﾠgroups	 ﾠby	 ﾠthe	 ﾠveterinary	 ﾠtechnician.	 ﾠ	 ﾠQuantitation	 ﾠand	 ﾠscoring	 ﾠof	 ﾠ
immunohistochemistry	 ﾠof	 ﾠPR,	 ﾠER,	 ﾠPCNA	 ﾠwere	 ﾠperformed	 ﾠby	 ﾠblinded	 ﾠindividuals,	 ﾠand	 ﾠtumor	 ﾠ
scoring	 ﾠwas	 ﾠconfirmed	 ﾠby	 ﾠa	 ﾠblinded	 ﾠpathologist.	 ﾠ	 ﾠ	 ﾠ	 ﾠ
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 ﾠ
Animals	 ﾠ
For	 ﾠtranscriptome	 ﾠanalysis,	 ﾠwhole	 ﾠmammary	 ﾠglands	 ﾠwere	 ﾠharvested	 ﾠfrom	 ﾠwild	 ﾠtype	 ﾠFVB	 ﾠmice	 ﾠat	 ﾠ
8	 ﾠweeks	 ﾠof	 ﾠage	 ﾠand	 ﾠtransgenic	 ﾠFVB	 ﾠC3(1)-ﾭ‐SV40Tag	 ﾠmice	 ﾠ(The	 ﾠJackson	 ﾠLaboratory,	 ﾠBar	 ﾠHarbor,	 ﾠ
ME)	 ﾠat	 ﾠ8,	 ﾠ12,	 ﾠ16	 ﾠ,	 ﾠand	 ﾠ20	 ﾠweeks	 ﾠof	 ﾠage	 ﾠ(n=5	 ﾠper	 ﾠtime	 ﾠpoint).	 ﾠAll	 ﾠanimal	 ﾠexperimental	 ﾠprotocols	 ﾠ
were	 ﾠapproved	 ﾠby	 ﾠthe	 ﾠInstitutional	 ﾠAnimal	 ﾠCare	 ﾠand	 ﾠUse	 ﾠCommittee	 ﾠof	 ﾠChildren’s	 ﾠHospital	 ﾠ
Boston.	 ﾠ	 ﾠ
	 ﾠ
Gene	 ﾠExpression	 ﾠAnalysis	 ﾠ
Tumor	 ﾠgene	 ﾠexpression	 ﾠprofiling	 ﾠwas	 ﾠcarried	 ﾠout	 ﾠusing	 ﾠMouse	 ﾠGenome	 ﾠMG	 ﾠ430	 ﾠ2.0	 ﾠAffymetrix	 ﾠ
GeneChip	 ﾠarrays.	 ﾠIn	 ﾠbrief,	 ﾠtotal	 ﾠRNA	 ﾠwas	 ﾠextracted	 ﾠfrom	 ﾠtissue	 ﾠwith	 ﾠthe	 ﾠRNeasy	 ﾠkit	 ﾠincluding	 ﾠ
DNase	 ﾠdigestion	 ﾠ(Qiagen).	 ﾠBiotinlabeled	 ﾠcDNA	 ﾠwas	 ﾠobtained	 ﾠfrom	 ﾠ1	 ﾠμg	 ﾠtotal	 ﾠRNA	 ﾠwith	 ﾠthe	 ﾠ
GeneChip	 ﾠOne-ﾭ‐Cycle	 ﾠlabeling	 ﾠkit	 ﾠ(Affymetrix).	 ﾠAccording	 ﾠto	 ﾠthe	 ﾠmanufacturer’s	 ﾠinstructions,	 ﾠ	 ﾠ1.5	 ﾠ
μg	 ﾠof	 ﾠcDNA	 ﾠwere	 ﾠfragmented	 ﾠand	 ﾠhybridized	 ﾠto	 ﾠAffymetrix	 ﾠMG	 ﾠ430	 ﾠ2.0	 ﾠGeneChip	 ﾠarrays.	 ﾠ	 ﾠArrays	 ﾠ
were	 ﾠprocessed	 ﾠby	 ﾠthe	 ﾠHarvard	 ﾠGenotyping	 ﾠand	 ﾠMicroarray	 ﾠCenter	 ﾠ(Boston,	 ﾠMA).	 ﾠDNA	 ﾠchips	 ﾠ
were	 ﾠwashed,	 ﾠstained	 ﾠand	 ﾠscanned	 ﾠusing	 ﾠan	 ﾠAffymetrix	 ﾠFluidics	 ﾠdevice	 ﾠand	 ﾠa	 ﾠGCS3000	 ﾠscanner,	 ﾠ
and	 ﾠthe	 ﾠimages	 ﾠobtained	 ﾠwere	 ﾠanalyzed	 ﾠusing	 ﾠGCOS	 ﾠsoftware.	 ﾠThe	 ﾠexperiment	 ﾠwas	 ﾠperformed	 ﾠ
in	 ﾠ5	 ﾠreplicates	 ﾠfor	 ﾠwild	 ﾠtype	 ﾠmice	 ﾠat	 ﾠ8	 ﾠweeks	 ﾠof	 ﾠage	 ﾠand	 ﾠtransgenic	 ﾠmice	 ﾠat	 ﾠ8,	 ﾠ12,	 ﾠ16,	 ﾠand	 ﾠ20	 ﾠ
weeks	 ﾠof	 ﾠage.	 ﾠData	 ﾠnormalization	 ﾠwas	 ﾠcalculated	 ﾠwith	 ﾠthe	 ﾠrobust	 ﾠmultichip	 ﾠaverage	 ﾠ(RMA)	 ﾠ
algorithm	 ﾠ(33)	 ﾠimplemented	 ﾠin	 ﾠBioConductor	 ﾠ(www.bioconductor.org).	 ﾠMG	 ﾠ430	 ﾠ2.0	 ﾠmRNA	 ﾠdata	 ﾠ
from	 ﾠeach	 ﾠindividual	 ﾠsample	 ﾠhave	 ﾠbeen	 ﾠdeposited	 ﾠwith	 ﾠthe	 ﾠNCBI	 ﾠGene	 ﾠExpression	 ﾠOmnibus	 ﾠ
(http://www.ncbi.nlm.nih.gov/geo/)	 ﾠunder	 ﾠaccession	 ﾠnumber	 ﾠGSE50813.	 ﾠ	 ﾠ
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Compendium	 ﾠGeneration	 ﾠfor	 ﾠMNI	 ﾠ
Approximately	 ﾠ11,000	 ﾠmouse	 ﾠmicroarrays	 ﾠdata	 ﾠwere	 ﾠcollected	 ﾠfrom	 ﾠthe	 ﾠNIH	 ﾠGene	 ﾠExpression	 ﾠ
Omnibus	 ﾠ(GEO).	 ﾠAll	 ﾠthe	 ﾠarrays	 ﾠwere	 ﾠprocessed	 ﾠbased	 ﾠon	 ﾠthe	 ﾠAffymetrix	 ﾠ430	 ﾠ2.0	 ﾠchip,	 ﾠwhich	 ﾠ
contains	 ﾠmore	 ﾠthan	 ﾠ45,000	 ﾠprobe	 ﾠsets	 ﾠrepresenting	 ﾠmore	 ﾠthan	 ﾠ34,000	 ﾠvalidated	 ﾠmouse	 ﾠgenes.	 ﾠ
Sequences	 ﾠused	 ﾠin	 ﾠthe	 ﾠdesign	 ﾠof	 ﾠthe	 ﾠarray	 ﾠwere	 ﾠselected	 ﾠfrom	 ﾠGenBank,	 ﾠdbEST,	 ﾠand	 ﾠRefSeq.	 ﾠ	 ﾠ
Eleven	 ﾠpairs	 ﾠof	 ﾠoligonucleotide	 ﾠprobes	 ﾠmeasure	 ﾠthe	 ﾠlevel	 ﾠof	 ﾠtranscription	 ﾠof	 ﾠeach	 ﾠsequence	 ﾠ
represented	 ﾠon	 ﾠthe	 ﾠGeneChip	 ﾠMouse	 ﾠGenome	 ﾠ430	 ﾠ2.0	 ﾠArray.	 ﾠData	 ﾠnormalization	 ﾠon	 ﾠthe	 ﾠtotal	 ﾠ
compendium	 ﾠwas	 ﾠcalculated	 ﾠwith	 ﾠthe	 ﾠrobust	 ﾠmultichip	 ﾠaverage	 ﾠ(RMA)	 ﾠalgorithm	 ﾠimplemented	 ﾠ
in	 ﾠBioConductor	 ﾠ(www.bioconductor.org)	 ﾠK-ﾭ‐mean	 ﾠclustering	 ﾠmethod	 ﾠwas	 ﾠapplied	 ﾠon	 ﾠthe	 ﾠtotal	 ﾠ
mouse	 ﾠcompendium	 ﾠdata	 ﾠand	 ﾠapproximately	 ﾠ3000	 ﾠmicroarrays	 ﾠwere	 ﾠselected	 ﾠas	 ﾠfinal	 ﾠtraining	 ﾠ
input	 ﾠdata	 ﾠset	 ﾠfor	 ﾠMNI.	 ﾠ	 ﾠ
	 ﾠ
MNI	 ﾠNetwork	 ﾠInference	 ﾠ
A	 ﾠdetailed	 ﾠdescription	 ﾠof	 ﾠthe	 ﾠMNI	 ﾠalgorithm	 ﾠand	 ﾠunderlying	 ﾠassumptions	 ﾠhas	 ﾠbeen	 ﾠpublished	 ﾠ
previously	 ﾠ(34).	 ﾠ	 ﾠHere	 ﾠwe	 ﾠprovide	 ﾠa	 ﾠbrief	 ﾠsummary	 ﾠwith	 ﾠadditional	 ﾠdetails	 ﾠavailable	 ﾠin	 ﾠ
Supplementary	 ﾠMethods.	 ﾠ	 ﾠThe	 ﾠalgorithm	 ﾠconsists	 ﾠof	 ﾠtwo	 ﾠphases.	 ﾠIn	 ﾠthe	 ﾠfirst	 ﾠ(the	 ﾠtraining	 ﾠphase),	 ﾠ
a	 ﾠmodel	 ﾠof	 ﾠregulatory	 ﾠinfluences	 ﾠin	 ﾠthe	 ﾠcell	 ﾠis	 ﾠlearned	 ﾠfrom	 ﾠan	 ﾠNxM	 ﾠdata	 ﾠmatrix,	 ﾠX,	 ﾠconsisting	 ﾠof	 ﾠ
measurements	 ﾠof	 ﾠsteady-ﾭ‐state	 ﾠexpression	 ﾠratios	 ﾠof	 ﾠN	 ﾠgenes	 ﾠin	 ﾠM	 ﾠexperiments.	 ﾠTo	 ﾠestimate	 ﾠthe	 ﾠ
network	 ﾠmodel	 ﾠA,	 ﾠthe	 ﾠMNI	 ﾠalgorithm	 ﾠuses	 ﾠa	 ﾠrecursive	 ﾠstrategy.	 ﾠ	 ﾠThe	 ﾠalgorithm	 ﾠbegins	 ﾠby	 ﾠusing	 ﾠ
the	 ﾠdata	 ﾠmatrix,	 ﾠX,	 ﾠand	 ﾠa	 ﾠnaive	 ﾠmodel	 ﾠof	 ﾠthe	 ﾠregulatory	 ﾠstructure	 ﾠ(i.e.	 ﾠno	 ﾠgenes	 ﾠregulate	 ﾠany	 ﾠ
other)	 ﾠto	 ﾠestimate	 ﾠP,	 ﾠan	 ﾠNxM	 ﾠmatrix	 ﾠof	 ﾠexternal	 ﾠinfluences	 ﾠon	 ﾠthe	 ﾠgenes.	 ﾠ	 ﾠThe	 ﾠestimate	 ﾠof	 ﾠP	 ﾠis	 ﾠ	 ﾠ
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then	 ﾠused,	 ﾠwith	 ﾠA,	 ﾠto	 ﾠdetermine	 ﾠA	 ﾠby	 ﾠprincipal	 ﾠcomponents	 ﾠregression	 ﾠanalysis.	 ﾠ	 ﾠEstimates	 ﾠof	 ﾠA	 ﾠ
and	 ﾠP	 ﾠare	 ﾠthen	 ﾠused	 ﾠto	 ﾠestimate	 ﾠone	 ﾠanother	 ﾠrecursively	 ﾠuntil	 ﾠthe	 ﾠestimates	 ﾠconverge.	 ﾠ	 ﾠIn	 ﾠthe	 ﾠ
second	 ﾠphase	 ﾠof	 ﾠthe	 ﾠalgorithm,	 ﾠthe	 ﾠA	 ﾠmatrix,	 ﾠrepresenting	 ﾠa	 ﾠmodel	 ﾠof	 ﾠregulatory	 ﾠinfluences	 ﾠin	 ﾠ
the	 ﾠcell,	 ﾠis	 ﾠused	 ﾠto	 ﾠestimate	 ﾠthe	 ﾠ“key	 ﾠmediator	 ﾠgenes”	 ﾠof	 ﾠthe	 ﾠdisease	 ﾠstage	 ﾠof	 ﾠinterest.	 ﾠ	 ﾠThe	 ﾠ
disease	 ﾠstage	 ﾠthen	 ﾠbecomes	 ﾠan	 ﾠNx1	 ﾠvector,	 ﾠp,	 ﾠof	 ﾠgene-ﾭ‐specific	 ﾠinfluences	 ﾠthat	 ﾠresult	 ﾠin	 ﾠthe	 ﾠlog-ﾭ‐
transformed	 ﾠexpression	 ﾠratios,	 ﾠx,	 ﾠmeasured	 ﾠfor	 ﾠthat	 ﾠdisease	 ﾠstate.	 ﾠ	 ﾠThe	 ﾠp	 ﾠvector	 ﾠis	 ﾠthen	 ﾠ
calculated	 ﾠdirectly	 ﾠfrom	 ﾠthe	 ﾠlog-ﾭ‐linear	 ﾠregulatory	 ﾠmodel	 ﾠas:	 ﾠP=Ax.	 ﾠ	 ﾠThe	 ﾠsignificance	 ﾠof	 ﾠeach	 ﾠ
element	 ﾠof	 ﾠthe	 ﾠp	 ﾠvector	 ﾠis	 ﾠthen	 ﾠcalculated	 ﾠas	 ﾠa	 ﾠz-ﾭ‐score.	 ﾠ	 ﾠGenes	 ﾠare	 ﾠranked	 ﾠaccording	 ﾠto	 ﾠthe	 ﾠz-ﾭ‐
score	 ﾠof	 ﾠtheir	 ﾠcorresponding	 ﾠelement	 ﾠin	 ﾠthe	 ﾠp	 ﾠvector	 ﾠand	 ﾠtop-ﾭ‐ranked	 ﾠgenes	 ﾠand	 ﾠpathways	 ﾠare	 ﾠ
selected	 ﾠas	 ﾠprobable	 ﾠkey	 ﾠmediators	 ﾠof	 ﾠthe	 ﾠdisease	 ﾠstate.	 ﾠ	 ﾠ
	 ﾠ
Cell	 ﾠCulture	 ﾠ
M6	 ﾠand	 ﾠM6C	 ﾠcell	 ﾠlines	 ﾠwere	 ﾠa	 ﾠkind	 ﾠgift	 ﾠfrom	 ﾠ	 ﾠC.	 ﾠJorczyk	 ﾠ(Boise	 ﾠState	 ﾠUniversity)	 ﾠand	 ﾠEph4	 ﾠcells	 ﾠ
were	 ﾠa	 ﾠgift	 ﾠfrom	 ﾠKevin	 ﾠFreeman	 ﾠ(Boston	 ﾠChildren’s	 ﾠHospital).	 ﾠ	 ﾠM6,	 ﾠM6C,	 ﾠand	 ﾠEph4	 ﾠcells	 ﾠwere	 ﾠ
maintained	 ﾠin	 ﾠhigh-ﾭ‐glucose	 ﾠ(4.5	 ﾠg/mL)	 ﾠDMEM	 ﾠgrowth	 ﾠmedia	 ﾠsupplemented	 ﾠwith	 ﾠ5%	 ﾠfetal	 ﾠbovine	 ﾠ
serum	 ﾠand	 ﾠ1%	 ﾠpenicillin/streptomycin.	 ﾠ	 ﾠHuman	 ﾠbreast	 ﾠand	 ﾠbreast	 ﾠcancer	 ﾠcell	 ﾠlines	 ﾠ(MCF10A,	 ﾠ
HCC1937	 ﾠand	 ﾠMDA-ﾭ‐MB-ﾭ‐468)	 ﾠwere	 ﾠpurchased	 ﾠfrom	 ﾠATCC.	 ﾠMCF10A	 ﾠcells	 ﾠwere	 ﾠmaintained	 ﾠin	 ﾠ
DMEM/F12	 ﾠgrowth	 ﾠmedia	 ﾠcontaining	 ﾠ5%	 ﾠequine	 ﾠserum,	 ﾠ20ng/ml	 ﾠEFG,	 ﾠ0.5	 ﾠµg/ml	 ﾠhydrocortisone,	 ﾠ
0.1	 ﾠµg/ml	 ﾠcholera	 ﾠtoxin,	 ﾠ10	 ﾠµg/ml	 ﾠinsulin	 ﾠand	 ﾠ1%	 ﾠpenicillin/streptomycin.	 ﾠHCC1937	 ﾠwere	 ﾠ
maintained	 ﾠin	 ﾠRPMI-ﾭ‐1640	 ﾠmedium	 ﾠwith	 ﾠ10%FBS	 ﾠand	 ﾠ1%	 ﾠpenicillin/streptomycin	 ﾠwhereas	 ﾠMDA-ﾭ‐
MB-ﾭ‐468	 ﾠcells	 ﾠwere	 ﾠgrown	 ﾠin	 ﾠLeibovitz’s	 ﾠL15	 ﾠmedium	 ﾠwith	 ﾠ10%	 ﾠFBS	 ﾠand	 ﾠ1%	 ﾠ	 ﾠ
	 ﾠ 18	 ﾠ
penicillin/streptomycin.	 ﾠWhereas	 ﾠall	 ﾠother	 ﾠcells	 ﾠwere	 ﾠmaintained	 ﾠat	 ﾠ37°C	 ﾠand	 ﾠ5%	 ﾠCO2,	 ﾠMDA-ﾭ‐MB-ﾭ‐
468	 ﾠcells	 ﾠwere	 ﾠgrown	 ﾠat	 ﾠ37°C	 ﾠand	 ﾠatmospheric	 ﾠair	 ﾠ(0%	 ﾠCO2).	 ﾠ
	 ﾠ
In	 ﾠvitro	 ﾠsilencing	 ﾠ
siRNA	 ﾠtargeting	 ﾠHoxA1	 ﾠwas	 ﾠpurchased	 ﾠfrom	 ﾠDharmacon	 ﾠ	 ﾠand	 ﾠtransfected	 ﾠinto	 ﾠM6,	 ﾠM6C,	 ﾠMD-ﾭ‐
MBA-ﾭ‐468	 ﾠor	 ﾠHCC1937	 ﾠcells	 ﾠusing	 ﾠ25	 ﾠnM	 ﾠusing	 ﾠDharmaFECT1	 ﾠreagent	 ﾠaccording	 ﾠto	 ﾠthe	 ﾠ
manufacturer’s	 ﾠprotocols.	 ﾠTarget	 ﾠsequences	 ﾠwere	 ﾠas	 ﾠfollows:	 ﾠsiRNA	 ﾠHoxA1_1:	 ﾠ5’	 ﾠ
CAACAAGUACCUUACACGA	 ﾠ3’;	 ﾠsiRNA	 ﾠHoxA1_	 ﾠ2:	 ﾠ5’	 ﾠCCAUAGGAUUACAACUUUCT	 ﾠ3’.	 ﾠA	 ﾠnon-ﾭ‐
targeting	 ﾠsequence	 ﾠ(ON-ﾭ‐TARGETplus	 ﾠD-ﾭ‐001810-ﾭ‐01)	 ﾠwas	 ﾠtransfected	 ﾠas	 ﾠa	 ﾠnegative	 ﾠcontrol.	 ﾠTo	 ﾠ
confirm	 ﾠthe	 ﾠeffectiveness	 ﾠof	 ﾠthe	 ﾠsilencing	 ﾠreagent	 ﾠin	 ﾠ3D	 ﾠcell	 ﾠculture,	 ﾠON-ﾭ‐TARGET	 ﾠGAPDH	 ﾠ
positive	 ﾠcontrol	 ﾠsiRNA	 ﾠwas	 ﾠalso	 ﾠtransfected.	 ﾠ	 ﾠCells	 ﾠwere	 ﾠmaintained	 ﾠin	 ﾠ3D	 ﾠculture	 ﾠfor	 ﾠ14	 ﾠdays	 ﾠ
and	 ﾠthen	 ﾠcollected	 ﾠfor	 ﾠanalysis	 ﾠby	 ﾠdissolution	 ﾠof	 ﾠthe	 ﾠgel	 ﾠwith	 ﾠcollagenase.	 ﾠ	 ﾠImmunoblotting	 ﾠ
confirmed	 ﾠeffective	 ﾠsilencing	 ﾠin	 ﾠcells	 ﾠusing	 ﾠrabbit	 ﾠanti-ﾭ‐HoxA1	 ﾠ(Abcam).	 ﾠ	 ﾠ	 ﾠ
	 ﾠ
Spheroid	 ﾠCulture	 ﾠin	 ﾠ3D	 ﾠGels	 ﾠ
Mammary	 ﾠepithelial	 ﾠand	 ﾠtumor	 ﾠcells	 ﾠdescribed	 ﾠabove	 ﾠwere	 ﾠtrypsinized,	 ﾠcentrifuged	 ﾠand	 ﾠ
resuspended	 ﾠin	 ﾠa	 ﾠ1:1	 ﾠsolution	 ﾠof	 ﾠtype	 ﾠI	 ﾠcollagen	 ﾠ(3	 ﾠmg/mL)	 ﾠand	 ﾠMatrigel	 ﾠand	 ﾠ	 ﾠadded	 ﾠto	 ﾠthe	 ﾠtop	 ﾠ
section	 ﾠof	 ﾠa	 ﾠ12-ﾭ‐mm	 ﾠtranswell	 ﾠplate	 ﾠwith	 ﾠ0.4-ﾭ‐μm	 ﾠpolycarbonate	 ﾠmembrane,	 ﾠsuch	 ﾠthat	 ﾠthe	 ﾠfinal	 ﾠ
cell	 ﾠnumber	 ﾠwas	 ﾠ100,000	 ﾠcells	 ﾠper	 ﾠwell.	 ﾠ	 ﾠGels	 ﾠwere	 ﾠallowed	 ﾠto	 ﾠharden	 ﾠat	 ﾠ37
oC	 ﾠfor	 ﾠ30	 ﾠmin	 ﾠbefore	 ﾠ
growth	 ﾠmedia	 ﾠwas	 ﾠadded	 ﾠto	 ﾠthe	 ﾠtop	 ﾠand	 ﾠbottom	 ﾠsections	 ﾠof	 ﾠthe	 ﾠtranswell	 ﾠplate.	 ﾠGel	 ﾠcultures	 ﾠ
were	 ﾠmaintained	 ﾠat	 ﾠ37
oC,	 ﾠ5%	 ﾠCO2	 ﾠfor	 ﾠ8-ﾭ‐14	 ﾠdays.	 ﾠ	 ﾠ	 ﾠGels	 ﾠwere	 ﾠthen	 ﾠfixed	 ﾠin	 ﾠ10%	 ﾠformalin	 ﾠ	 ﾠ
	 ﾠ 19	 ﾠ
overnight	 ﾠand	 ﾠthe	 ﾠtranswell	 ﾠmembrane	 ﾠcontaining	 ﾠthe	 ﾠgel	 ﾠwas	 ﾠremoved	 ﾠfrom	 ﾠthe	 ﾠculture	 ﾠ
chamber	 ﾠprior	 ﾠto	 ﾠcarmine	 ﾠstaining	 ﾠor	 ﾠsectioning.	 ﾠ	 ﾠ
	 ﾠ
In	 ﾠvivo	 ﾠRNAi	 ﾠDelivery	 ﾠ
siRNA	 ﾠwas	 ﾠformulated	 ﾠwith	 ﾠlipid-ﾭ‐like	 ﾠamino	 ﾠalcohols	 ﾠ(lipidoids)	 ﾠas	 ﾠdescribed	 ﾠpreviously	 ﾠ(47).	 ﾠ
Particle	 ﾠsizes	 ﾠwere	 ﾠmeasured	 ﾠby	 ﾠdynamic	 ﾠlight	 ﾠscattering	 ﾠusing	 ﾠa	 ﾠMalvern	 ﾠZetasizer	 ﾠNanoZS	 ﾠ
(Malvern).	 ﾠsiRNA	 ﾠ(20	 ﾠµg)	 ﾠwas	 ﾠdelivered	 ﾠintraductally	 ﾠto	 ﾠthe	 ﾠthoracic	 ﾠgland	 ﾠof	 ﾠthe	 ﾠmouse	 ﾠthrough	 ﾠ
the	 ﾠnipple	 ﾠusing	 ﾠa	 ﾠ33	 ﾠG	 ﾠneedle	 ﾠwhile	 ﾠvisualizing	 ﾠthe	 ﾠnipple	 ﾠsite	 ﾠunder	 ﾠa	 ﾠstereoscope	 ﾠ(48).	 ﾠ	 ﾠ
Fluorescently	 ﾠtagged	 ﾠsiRNA	 ﾠ(Dharmafect	 ﾠsiGLO)	 ﾠand	 ﾠEvans	 ﾠblue	 ﾠvital	 ﾠdye	 ﾠwere	 ﾠused	 ﾠto	 ﾠ
determine	 ﾠthe	 ﾠvolume	 ﾠneeded	 ﾠto	 ﾠfill	 ﾠthe	 ﾠmammary	 ﾠductal	 ﾠtree	 ﾠcompletely	 ﾠwithout	 ﾠperforating	 ﾠ
the	 ﾠwall	 ﾠof	 ﾠthe	 ﾠduct).	 ﾠFollowing	 ﾠinjection,	 ﾠglands	 ﾠwere	 ﾠimaged	 ﾠweekly	 ﾠwith	 ﾠa	 ﾠVEVO	 ﾠ2100	 ﾠ
VisualSonic	 ﾠultrasound	 ﾠmachine	 ﾠin	 ﾠorder	 ﾠto	 ﾠdetermine	 ﾠthe	 ﾠonset,	 ﾠnumber,	 ﾠsize,	 ﾠand	 ﾠlocation	 ﾠof	 ﾠ
tumors.	 ﾠ
	 ﾠ
Protein	 ﾠisolation	 ﾠand	 ﾠimmunoblotting	 ﾠ
Tissues	 ﾠwere	 ﾠwashed	 ﾠonce	 ﾠin	 ﾠ500	 ﾠµl	 ﾠof	 ﾠice-ﾭ‐cold	 ﾠBio-ﾭ‐Rad	 ﾠBioPlex	 ﾠCell	 ﾠWash	 ﾠBuffer,	 ﾠcut	 ﾠinto	 ﾠ3x3	 ﾠ
mm	 ﾠpieces,	 ﾠand	 ﾠhomogenized	 ﾠin	 ﾠ500	 ﾠµl	 ﾠof	 ﾠice-ﾭ‐cold	 ﾠBio-ﾭ‐Rad	 ﾠBioPlex	 ﾠCell	 ﾠLysis	 ﾠBuffer	 ﾠusing	 ﾠan	 ﾠIKA	 ﾠ
T10	 ﾠBasic	 ﾠUltra-ﾭ‐Turrax	 ﾠhomogenizer	 ﾠ(dispersing	 ﾠelement	 ﾠS10N-ﾭ‐5G)	 ﾠfor	 ﾠ30	 ﾠs	 ﾠat	 ﾠminimum	 ﾠspeed	 ﾠ
and	 ﾠ15	 ﾠs	 ﾠat	 ﾠmaximum	 ﾠspeed.	 ﾠHomogenates	 ﾠwere	 ﾠfrozen	 ﾠat	 ﾠ-ﾭ‐80
oC	 ﾠto	 ﾠcomplete	 ﾠthe	 ﾠlysis,	 ﾠthawed,	 ﾠ
and	 ﾠcentrifuged	 ﾠat	 ﾠ4
oC,	 ﾠ8000	 ﾠrcf,	 ﾠfor	 ﾠ20	 ﾠmin,	 ﾠfollowed	 ﾠby	 ﾠisolation	 ﾠof	 ﾠthe	 ﾠsoluble	 ﾠlayer.	 ﾠProtein	 ﾠ
concentrations	 ﾠwere	 ﾠmeasured	 ﾠusing	 ﾠBio-ﾭ‐Rad	 ﾠDC	 ﾠProtein	 ﾠAssay	 ﾠon	 ﾠNanoDrop	 ﾠ2000.	 ﾠThe	 ﾠ
following	 ﾠprimary	 ﾠantibodies	 ﾠwere	 ﾠused	 ﾠfor	 ﾠimmunoblotting:	 ﾠ1:10,000	 ﾠrabbit	 ﾠanti-ﾭ‐PCNA	 ﾠ(Novus	 ﾠ	 ﾠ
	 ﾠ 20	 ﾠ
Biologicals),	 ﾠ1:2000	 ﾠrabbit	 ﾠanti-ﾭ‐Src	 ﾠ(Cell	 ﾠSignaling	 ﾠTechnology),	 ﾠ1:500	 ﾠgoat	 ﾠanti-ﾭ‐Grb2	 ﾠ(R&D	 ﾠ
Systems),	 ﾠ1:1000	 ﾠrabbit	 ﾠanti-ﾭ‐ERK1/2	 ﾠ(R&D	 ﾠSystems),	 ﾠ1:2000	 ﾠrabbit	 ﾠanti-ﾭ‐IER3	 ﾠ(Novus	 ﾠBiologicals),	 ﾠ
1:5000	 ﾠrabbit	 ﾠanti-ﾭ‐KRAS	 ﾠ(Novus	 ﾠBiologicals),	 ﾠ1:1000	 ﾠrabbit-ﾭ‐anti-ﾭ‐HoxA1	 ﾠ(Abcam).	 ﾠ	 ﾠ
	 ﾠ
Immunohistochemistry	 ﾠ	 ﾠ
Parallel	 ﾠgel	 ﾠsamples	 ﾠwere	 ﾠprocessed	 ﾠfor	 ﾠfrozen	 ﾠand	 ﾠparaffin	 ﾠembedded	 ﾠsections.	 ﾠ	 ﾠFollowing	 ﾠ
formalin	 ﾠfixation	 ﾠto	 ﾠobtain	 ﾠfrozen	 ﾠsections,	 ﾠgels	 ﾠwere	 ﾠwashed	 ﾠwith	 ﾠPBS	 ﾠand	 ﾠplaced	 ﾠin	 ﾠOCT	 ﾠ
(TissueTek)	 ﾠwith	 ﾠ30%	 ﾠsucrose	 ﾠat	 ﾠ4
oC	 ﾠovernight.	 ﾠ	 ﾠGels	 ﾠwere	 ﾠthen	 ﾠflash	 ﾠfrozen	 ﾠon	 ﾠliquid	 ﾠN2	 ﾠand	 ﾠ8-ﾭ‐
10	 ﾠμm	 ﾠsections	 ﾠwere	 ﾠprepared	 ﾠusing	 ﾠa	 ﾠcryostat	 ﾠ(Leica).	 ﾠ	 ﾠStaining	 ﾠof	 ﾠgels	 ﾠwas	 ﾠcarried	 ﾠout	 ﾠwith	 ﾠthe	 ﾠ
following	 ﾠantibodies	 ﾠand	 ﾠconcentrations:	 ﾠ1:100	 ﾠmouse	 ﾠanti-ﾭ‐GM130	 ﾠ(BD	 ﾠBiosciences),	 ﾠ1:100	 ﾠ
rabbit	 ﾠanti-ﾭ‐laminin-ﾭ‐5	 ﾠ(Abcam),	 ﾠ1:200	 ﾠrabbit	 ﾠanti-ﾭ‐ZO1	 ﾠ(Invitrogen),	 ﾠand	 ﾠTUNEL	 ﾠstain	 ﾠ(Roche	 ﾠkit).	 ﾠ	 ﾠ
Paraffin-ﾭ‐embedded	 ﾠgel	 ﾠsections	 ﾠwere	 ﾠstained	 ﾠwith	 ﾠ1:200	 ﾠrat	 ﾠanti-ﾭ‐BrdU	 ﾠ(Abcam).	 ﾠ	 ﾠParaffin	 ﾠtissue	 ﾠ
sections	 ﾠwere	 ﾠprepared	 ﾠby	 ﾠthe	 ﾠHarvard	 ﾠMedical	 ﾠSchool	 ﾠhistology	 ﾠcore	 ﾠfacility	 ﾠand	 ﾠstained	 ﾠwith	 ﾠ
1:100	 ﾠanti-ﾭ‐ER	 ﾠ(Abcam),	 ﾠ1:400	 ﾠanti-ﾭ‐PR	 ﾠ(Dako),	 ﾠ1:100	 ﾠanti-ﾭ‐PCNA	 ﾠ(Dako)	 ﾠand	 ﾠTUNEL	 ﾠ(Roche).	 ﾠ	 ﾠ
Stained	 ﾠsections	 ﾠwere	 ﾠimaged	 ﾠat	 ﾠ40X	 ﾠusing	 ﾠa	 ﾠZeiss	 ﾠImager	 ﾠand	 ﾠcells	 ﾠfrom	 ﾠat	 ﾠleast	 ﾠ5	 ﾠ
representative	 ﾠfields	 ﾠwere	 ﾠquantified	 ﾠper	 ﾠanimal.	 ﾠ	 ﾠ	 ﾠ
	 ﾠ
Microscopic	 ﾠAnalysis	 ﾠand	 ﾠQuantitation	 ﾠ
Confocal	 ﾠimages	 ﾠof	 ﾠ3D	 ﾠspheroids	 ﾠin	 ﾠcollagen/Matrigel	 ﾠwere	 ﾠobtained	 ﾠon	 ﾠa	 ﾠLeica	 ﾠwhite	 ﾠlaser	 ﾠ
Leica	 ﾠSP5	 ﾠX	 ﾠmultispectral-ﾭ‐multiphoton	 ﾠconfocal	 ﾠsystem.	 ﾠImages	 ﾠwere	 ﾠacquired	 ﾠthroughout	 ﾠthe	 ﾠ
intact	 ﾠgel	 ﾠwith	 ﾠ2-ﾭ‐μm	 ﾠresolution	 ﾠto	 ﾠverify	 ﾠformation	 ﾠof	 ﾠa	 ﾠhollow	 ﾠcentral	 ﾠlumen.	 ﾠSections	 ﾠand	 ﾠ2D	 ﾠ
cultures	 ﾠwere	 ﾠimaged	 ﾠon	 ﾠa	 ﾠZeiss	 ﾠAxio	 ﾠObserver	 ﾠZ1	 ﾠwith	 ﾠa	 ﾠCoolSNAP	 ﾠcamera.	 ﾠ	 ﾠBrightfield	 ﾠimaging	 ﾠ	 ﾠ
	 ﾠ 21	 ﾠ
was	 ﾠcarried	 ﾠout	 ﾠwith	 ﾠa	 ﾠZeiss	 ﾠAxio	 ﾠObserver	 ﾠwith	 ﾠNuance	 ﾠcolor	 ﾠcamera	 ﾠand	 ﾠmultispectral	 ﾠimaging	 ﾠ
system.	 ﾠInform	 ﾠsoftware	 ﾠpackage	 ﾠ(CRI)	 ﾠwas	 ﾠused	 ﾠto	 ﾠperform	 ﾠautomated	 ﾠquantitation	 ﾠof	 ﾠ
proliferative	 ﾠand	 ﾠapoptotic	 ﾠindices.	 ﾠMetaMorph	 ﾠsoftware	 ﾠwas	 ﾠused	 ﾠto	 ﾠperform	 ﾠmorphometric	 ﾠ
analysis	 ﾠof	 ﾠlumen	 ﾠformation.	 ﾠSpheroids	 ﾠfrom	 ﾠthree	 ﾠindependent	 ﾠexperiments	 ﾠwere	 ﾠquantified	 ﾠ
for	 ﾠeach	 ﾠsample	 ﾠand	 ﾠ180-ﾭ‐200	 ﾠcells	 ﾠwere	 ﾠscored	 ﾠper	 ﾠcondition	 ﾠfor	 ﾠeach	 ﾠassay.	 ﾠ	 ﾠ
	 ﾠ
Statistical	 ﾠanalysis	 ﾠ
All	 ﾠin	 ﾠvitro	 ﾠassays	 ﾠwere	 ﾠperformed	 ﾠin	 ﾠtriplicate.	 ﾠ	 ﾠData	 ﾠare	 ﾠreported	 ﾠas	 ﾠmeans	 ﾠ+/-ﾭ‐	 ﾠSD	 ﾠfor	 ﾠn=3	 ﾠ
assays.	 ﾠ	 ﾠIn	 ﾠvivo	 ﾠquantitation	 ﾠwas	 ﾠperformed	 ﾠon	 ﾠsamples	 ﾠfrom	 ﾠn=5	 ﾠanimals	 ﾠto	 ﾠaccount	 ﾠfor	 ﾠ
potential	 ﾠheterogeneity.	 ﾠ	 ﾠData	 ﾠare	 ﾠreported	 ﾠas	 ﾠmeans	 ﾠ+/-ﾭ‐	 ﾠSEM	 ﾠfor	 ﾠassays	 ﾠin	 ﾠwhich	 ﾠn>5	 ﾠsamples	 ﾠ
were	 ﾠquantified.	 ﾠ	 ﾠFor	 ﾠnon-ﾭ‐continuous	 ﾠvariables,	 ﾠp-ﾭ‐values	 ﾠwere	 ﾠdetermined	 ﾠby	 ﾠPearson’s	 ﾠchi-ﾭ‐




Materials	 ﾠand	 ﾠMethods	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 ﾠ
Fig.	 ﾠS1.	 ﾠConventional	 ﾠbioinformatics	 ﾠanalysis	 ﾠof	 ﾠmammary	 ﾠgland	 ﾠgene	 ﾠexpression	 ﾠchanges	 ﾠin	 ﾠ
C3(1)-ﾭ‐SV40Tag–driven	 ﾠtumorigenesis.	 ﾠ
	 ﾠ
Fig.	 ﾠS2.	 ﾠSilencing	 ﾠof	 ﾠHoxA1	 ﾠin	 ﾠhuman	 ﾠcell	 ﾠlines	 ﾠin	 ﾠvitro.	 ﾠ
	 ﾠ
Fig.	 ﾠS3.	 ﾠIn	 ﾠvivo	 ﾠdelivery	 ﾠof	 ﾠsiRNA	 ﾠto	 ﾠthe	 ﾠmammary	 ﾠductal	 ﾠtree.	 ﾠ	 ﾠ
	 ﾠ
Fig.	 ﾠS4.	 ﾠ	 ﾠMonitoring	 ﾠsystemic	 ﾠresponse	 ﾠto	 ﾠin	 ﾠvivo	 ﾠRNAi.	 ﾠ	 ﾠ	 ﾠ
   	 ﾠ
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Figure	 ﾠ1.	 ﾠ	 ﾠGene	 ﾠnetwork	 ﾠinference	 ﾠpipeline.	 ﾠIn	 ﾠthe	 ﾠfirst	 ﾠphase,	 ﾠthe	 ﾠMNI	 ﾠalgorithm	 ﾠwas	 ﾠtrained	 ﾠ
on	 ﾠa	 ﾠcompendium	 ﾠof	 ﾠ3000	 ﾠmouse	 ﾠmicroarray	 ﾠdata	 ﾠsets	 ﾠto	 ﾠconstruct	 ﾠa	 ﾠbasal	 ﾠnetwork	 ﾠ
connectivity	 ﾠmodel.	 ﾠGenome-ﾭ‐wide	 ﾠexpression	 ﾠdata	 ﾠfrom	 ﾠwild	 ﾠtype	 ﾠand	 ﾠ8	 ﾠweek-ﾭ‐old	 ﾠtransgenic	 ﾠ
mammary	 ﾠglands	 ﾠwere	 ﾠthen	 ﾠinterrogated	 ﾠusing	 ﾠthe	 ﾠGRN	 ﾠmodel	 ﾠto	 ﾠpinpoint	 ﾠalterations	 ﾠin	 ﾠgene	 ﾠ
behavior	 ﾠthat	 ﾠwere	 ﾠunique	 ﾠto	 ﾠparticular	 ﾠstages	 ﾠof	 ﾠtumorigenesis.	 ﾠThe	 ﾠsignificance	 ﾠof	 ﾠthe	 ﾠ
predicted	 ﾠkey	 ﾠmediator	 ﾠgenes	 ﾠof	 ﾠthe	 ﾠdisease	 ﾠstage	 ﾠof	 ﾠinterest	 ﾠis	 ﾠquantified	 ﾠwith	 ﾠa	 ﾠz-ﾭ‐score.	 ﾠTwo-ﾭ‐
tailed	 ﾠp-ﾭ‐values	 ﾠare	 ﾠcalculated	 ﾠbased	 ﾠon	 ﾠthe	 ﾠz-ﾭ‐score	 ﾠvalue.	 ﾠGenes	 ﾠare	 ﾠranked	 ﾠaccording	 ﾠto	 ﾠthe	 ﾠp-ﾭ‐
value,	 ﾠand	 ﾠtop-ﾭ‐ranked	 ﾠgenes	 ﾠare	 ﾠselected	 ﾠas	 ﾠprobable	 ﾠkey	 ﾠmediators	 ﾠof	 ﾠthe	 ﾠdisease	 ﾠstate.	 ﾠ	 ﾠ
	 ﾠ
Figure	 ﾠ2.	 ﾠ	 ﾠIn	 ﾠvitro	 ﾠsilencing	 ﾠof	 ﾠHoxA1	 ﾠnormalizes	 ﾠmouse	 ﾠmammary	 ﾠtumor	 ﾠcell	 ﾠspheroid	 ﾠ
cultures,	 ﾠrestoring	 ﾠpolarity	 ﾠand	 ﾠreducing	 ﾠproliferative	 ﾠindex.	 ﾠ(A)	 ﾠDisease	 ﾠprogression	 ﾠin	 ﾠthe	 ﾠ
C3(1)-ﾭ‐SV40TAg	 ﾠglands	 ﾠis	 ﾠmarked	 ﾠby	 ﾠatypia	 ﾠand	 ﾠhyperplasia,	 ﾠductal	 ﾠfilling	 ﾠand	 ﾠtumor	 ﾠinvasion	 ﾠ
(H&E)	 ﾠwith	 ﾠa	 ﾠprogressive	 ﾠloss	 ﾠof	 ﾠGM130	 ﾠ(green)	 ﾠand	 ﾠlaminin	 ﾠ(red)	 ﾠpolarity	 ﾠby	 ﾠ12	 ﾠweeks	 ﾠand	 ﾠ
basement	 ﾠmembrane	 ﾠthinning	 ﾠby	 ﾠ16	 ﾠweeks.	 ﾠ	 ﾠScale	 ﾠbars,	 ﾠ100	 ﾠµm.	 ﾠ	 ﾠ(B)	 ﾠConfocal	 ﾠimages	 ﾠthrough	 ﾠ
the	 ﾠcenter	 ﾠof	 ﾠcarmine-ﾭ‐labeled	 ﾠnormal	 ﾠmouse	 ﾠmammary	 ﾠ(Eph4)	 ﾠand	 ﾠmouse	 ﾠmammary	 ﾠtumor	 ﾠ
(M6	 ﾠand	 ﾠM6C)	 ﾠspheroid	 ﾠcultures	 ﾠreveal	 ﾠfilled	 ﾠlumens	 ﾠin	 ﾠtumor	 ﾠcell	 ﾠcultures	 ﾠand	 ﾠa	 ﾠhollow	 ﾠ
organized	 ﾠlumen	 ﾠmorphology	 ﾠwhen	 ﾠHoxA1	 ﾠis	 ﾠsilenced.	 ﾠCell	 ﾠpolarity	 ﾠwas	 ﾠvisualized	 ﾠby	 ﾠ
immunocytochemistry	 ﾠof	 ﾠsectioned	 ﾠspheroids	 ﾠwith	 ﾠstaining	 ﾠof	 ﾠan	 ﾠapical	 ﾠGolgi	 ﾠmarker	 ﾠGM130	 ﾠ
and	 ﾠthe	 ﾠbasal	 ﾠbasement	 ﾠmembrane	 ﾠprotein,	 ﾠlaminin.	 ﾠ	 ﾠNuclei	 ﾠare	 ﾠstained	 ﾠwith	 ﾠDAPI	 ﾠ(blue)	 ﾠand	 ﾠF-ﾭ‐
actin	 ﾠis	 ﾠlabeled	 ﾠwith	 ﾠphalloidin	 ﾠ(green).	 ﾠ	 ﾠScale	 ﾠbars,	 ﾠ20	 ﾠµm.	 ﾠImages	 ﾠrepresentative	 ﾠof	 ﾠn	 ﾠ=	 ﾠ3	 ﾠ
studies,	 ﾠ150-ﾭ‐300	 ﾠspheroids	 ﾠimaged	 ﾠper	 ﾠsample)	 ﾠ	 ﾠDownregulation	 ﾠof	 ﾠHoxA1	 ﾠprotein	 ﾠexpression	 ﾠ	 ﾠ
	 ﾠ 26	 ﾠ
was	 ﾠconfirmed	 ﾠby	 ﾠimmunoblotting	 ﾠin	 ﾠlysates	 ﾠprepared	 ﾠfrom	 ﾠM6	 ﾠand	 ﾠM6C	 ﾠcells	 ﾠ(n=3).	 ﾠ	 ﾠ(C	 ﾠand	 ﾠD)	 ﾠ
The	 ﾠeffects	 ﾠof	 ﾠsilencing	 ﾠHoxA1	 ﾠon	 ﾠhollow	 ﾠlumen	 ﾠformation	 ﾠ(C)	 ﾠand	 ﾠcell	 ﾠproliferation	 ﾠ(D)	 ﾠin	 ﾠ
collagen-ﾭ‐Matrigel	 ﾠspheroid	 ﾠcultures	 ﾠof	 ﾠmouse	 ﾠM6	 ﾠand	 ﾠM6C	 ﾠtumor	 ﾠcells.	 ﾠEph4	 ﾠmouse	 ﾠmammary	 ﾠ
cells	 ﾠserved	 ﾠas	 ﾠnormal	 ﾠcontrols.	 ﾠData	 ﾠare	 ﾠmeans	 ﾠ+/-ﾭ‐	 ﾠSD	 ﾠ(n	 ﾠ=	 ﾠ3,	 ﾠ150-ﾭ‐300	 ﾠspheroids	 ﾠimaged	 ﾠper	 ﾠ
sample;	 ﾠ*p	 ﾠ<	 ﾠ0.05,	 ﾠ**p<0.01,	 ﾠFisher’s	 ﾠexact	 ﾠt-ﾭ‐test).	 ﾠ(E)	 ﾠQuantitation	 ﾠof	 ﾠapoptosis	 ﾠby	 ﾠTUNEL	 ﾠ
staining	 ﾠafter	 ﾠtreatment	 ﾠof	 ﾠM6	 ﾠand	 ﾠM6C	 ﾠcells	 ﾠwith	 ﾠHoxA1	 ﾠsiRNA	 ﾠ	 ﾠ(n=3,	 ﾠ150-ﾭ‐300	 ﾠspheroids	 ﾠ
imaged	 ﾠper	 ﾠsample)	 ﾠ*p<0.05,	 ﾠFisher’s	 ﾠexact	 ﾠt-ﾭ‐test.	 ﾠ
	 ﾠ
Figure	 ﾠ3.	 ﾠ	 ﾠSilencing	 ﾠHoxA1	 ﾠin	 ﾠhuman	 ﾠbreast	 ﾠcancer	 ﾠcells	 ﾠreduces	 ﾠcell	 ﾠgrowth	 ﾠand	 ﾠrestores	 ﾠ
lumen	 ﾠorganization	 ﾠin	 ﾠtumor	 ﾠcell	 ﾠspheroid	 ﾠcultures.	 ﾠ	 ﾠ(A)	 ﾠThe	 ﾠOncomine	 ﾠcompendium	 ﾠof	 ﾠcancer	 ﾠ
transcriptome	 ﾠprofiles	 ﾠwas	 ﾠused	 ﾠfor	 ﾠanalysis	 ﾠand	 ﾠvisualization	 ﾠof	 ﾠHoxA1	 ﾠexpression	 ﾠdata	 ﾠin	 ﾠ
human	 ﾠbreast	 ﾠtumors	 ﾠand	 ﾠnormal	 ﾠbreast	 ﾠtissue.	 ﾠ	 ﾠDifferential	 ﾠexpression	 ﾠanalysis	 ﾠidentified	 ﾠ10	 ﾠ
patient	 ﾠdatasets	 ﾠin	 ﾠwhich	 ﾠHoxA1	 ﾠwas	 ﾠover-ﾭ‐expressed	 ﾠin	 ﾠhuman	 ﾠbreast	 ﾠlesions	 ﾠby	 ﾠgreater	 ﾠthan	 ﾠ2-ﾭ‐
fold	 ﾠ(see	 ﾠreferences	 ﾠ26-ﾭ‐31).	 ﾠ	 ﾠThe	 ﾠtype	 ﾠof	 ﾠtumor	 ﾠrepresented	 ﾠin	 ﾠthe	 ﾠdatasets	 ﾠis	 ﾠcategorized	 ﾠas	 ﾠD,	 ﾠ
ductal	 ﾠbreast	 ﾠcarcinomas;	 ﾠL,	 ﾠlobular	 ﾠbreast	 ﾠcarcinomas;	 ﾠA;	 ﾠall	 ﾠbreast	 ﾠcarcinomas.	 ﾠThe	 ﾠrank	 ﾠorder	 ﾠ
of	 ﾠHoxA1	 ﾠin	 ﾠeach	 ﾠanalysis	 ﾠis	 ﾠdisplayed	 ﾠ(red,	 ﾠincreased	 ﾠrank	 ﾠ%;	 ﾠblue,	 ﾠdecreased	 ﾠrank	 ﾠ%).	 ﾠ(B)	 ﾠ
Confocal	 ﾠimages	 ﾠthrough	 ﾠthe	 ﾠcenter	 ﾠof	 ﾠcarmine-ﾭ‐labeled	 ﾠspheroid	 ﾠcultures	 ﾠof	 ﾠnormal	 ﾠhuman	 ﾠ
breast	 ﾠepithelial	 ﾠcells	 ﾠ(MCF10A)	 ﾠand	 ﾠhuman	 ﾠbreast	 ﾠcancer	 ﾠMD-ﾭ‐MBA-ﾭ‐468	 ﾠand	 ﾠHCC1937	 ﾠcell	 ﾠlines	 ﾠ
reveal.	 ﾠBreast	 ﾠcancer	 ﾠcells	 ﾠwere	 ﾠalso	 ﾠtreated	 ﾠwithsiHoxA1.	 ﾠ	 ﾠScale	 ﾠbar,	 ﾠ20	 ﾠµm.	 ﾠ(C)	 ﾠHollow	 ﾠlumen	 ﾠ
formation	 ﾠand	 ﾠ(D)	 ﾠproliferation	 ﾠof	 ﾠcancer	 ﾠcells	 ﾠin	 ﾠcollagen-ﾭ‐Matrigel	 ﾠspheroid	 ﾠcultures.	 ﾠ	 ﾠ
Quantitation	 ﾠof	 ﾠlumen	 ﾠformation	 ﾠin	 ﾠnon-ﾭ‐tumorigenic	 ﾠhuman	 ﾠMCF10A	 ﾠbreast	 ﾠepithelial	 ﾠcells	 ﾠand	 ﾠ
cells	 ﾠtreated	 ﾠwith	 ﾠscrambled	 ﾠsiRNA	 ﾠcontrols	 ﾠare	 ﾠshown	 ﾠfor	 ﾠcomparison.	 ﾠ	 ﾠData	 ﾠare	 ﾠmeans	 ﾠ+/-ﾭ‐	 ﾠSD	 ﾠ
(n	 ﾠ=	 ﾠ3,	 ﾠ150-ﾭ‐300	 ﾠcells	 ﾠper	 ﾠsample)	 ﾠ**p<0.01,	 ﾠFisher’s	 ﾠexact	 ﾠt-ﾭ‐test.	 ﾠ	 ﾠ	 ﾠ	 ﾠ
	 ﾠ
Figure	 ﾠ 4.	 ﾠ Silencing	 ﾠ HoxA1	 ﾠ in	 ﾠ the	 ﾠ mammary	 ﾠ epithelium	 ﾠ reduces	 ﾠ tumor	 ﾠ incidence,	 ﾠ reduces	 ﾠ
proliferative	 ﾠindex,	 ﾠand	 ﾠprevents	 ﾠthe	 ﾠloss	 ﾠof	 ﾠhormone	 ﾠreceptor	 ﾠexpression.	 ﾠ(A)	 ﾠVirgin	 ﾠC3(1)-ﾭ‐
SV40TAg	 ﾠ mammary	 ﾠ glands	 ﾠ injected	 ﾠ in	 ﾠ parallel	 ﾠ with	 ﾠ 20	 ﾠ µl	 ﾠ of	 ﾠ a	 ﾠ fluorescent	 ﾠ control	 ﾠ siRNA-ﾭ‐
nanoparticle	 ﾠto	 ﾠvisualize	 ﾠthe	 ﾠefficiency	 ﾠof	 ﾠits	 ﾠdelivery	 ﾠthroughout	 ﾠthe	 ﾠductal	 ﾠtree.	 ﾠThe	 ﾠentire	 ﾠ
injected	 ﾠgland	 ﾠwas	 ﾠremoved	 ﾠand	 ﾠwhole	 ﾠmounted	 ﾠfor	 ﾠfluorescent	 ﾠimaging.	 ﾠScale	 ﾠbar,	 ﾠ1	 ﾠmm.	 ﾠ(B)	 ﾠ
Confocal	 ﾠimages	 ﾠof	 ﾠmammary	 ﾠtissue	 ﾠsections	 ﾠshow	 ﾠdistribution	 ﾠof	 ﾠfluorescent	 ﾠcontrol	 ﾠsiRNA	 ﾠ
(red)	 ﾠin	 ﾠthe	 ﾠduct	 ﾠat	 ﾠ2,	 ﾠ7,	 ﾠand	 ﾠ14	 ﾠdays	 ﾠpost-ﾭ‐injection.	 ﾠTissues	 ﾠwere	 ﾠcounterstained	 ﾠwith	 ﾠlaminin	 ﾠ
(green)	 ﾠand	 ﾠDAPI	 ﾠ(blue).	 ﾠBar=	 ﾠ100	 ﾠµm. (C)	 ﾠTumor	 ﾠincidence	 ﾠmeasured	 ﾠat	 ﾠ21	 ﾠweeks	 ﾠin	 ﾠcontrol	 ﾠ
C3(1)-ﾭ‐SV40TAg	 ﾠmice	 ﾠversus	 ﾠmice	 ﾠinjected	 ﾠwith	 ﾠsiHoxA1	 ﾠbi-ﾭ‐weekly	 ﾠfor	 ﾠ9	 ﾠweeks	 ﾠ(n=10	 ﾠsiNT,	 ﾠn=8	 ﾠ
siHoxA1,	 ﾠ	 ﾠn=5	 ﾠuntreated).	 ﾠ(D)	 ﾠTiming	 ﾠof	 ﾠonset	 ﾠof	 ﾠtumor	 ﾠformation	 ﾠin	 ﾠuntreated,	 ﾠsiNT	 ﾠcontrol,	 ﾠ
and	 ﾠ siHoxA1	 ﾠ treated	 ﾠ mice.	 ﾠ (E)	 ﾠ H&E	 ﾠ and	 ﾠ F)	 ﾠ immunohistochemistry	 ﾠ for	 ﾠ PR,	 ﾠ ER,and	 ﾠ PCNA	 ﾠ in	 ﾠ
mammary	 ﾠglands.	 ﾠScale	 ﾠbar,	 ﾠ20	 ﾠµm.	 ﾠ(G,	 ﾠH,	 ﾠI)	 ﾠPercentage	 ﾠof	 ﾠPCNA+,	 ﾠER+,	 ﾠPR+	 ﾠcells	 ﾠafter	 ﾠ9	 ﾠweeks	 ﾠ
of	 ﾠtreatment	 ﾠare	 ﾠshown	 ﾠin	 ﾠData	 ﾠare	 ﾠmean	 ﾠ+/-ﾭ‐	 ﾠSEM,	 ﾠn=5	 ﾠanimals,	 ﾠ400-ﾭ‐550	 ﾠcells	 ﾠscored	 ﾠper	 ﾠanimal,	 ﾠ
**p<0.01,	 ﾠ***p<	 ﾠ0.001,	 ﾠPearson’s	 ﾠchi-ﾭ‐square	 ﾠtest.	 ﾠ(For	 ﾠeach	 ﾠsample,	 ﾠdata).	 ﾠ	 ﾠ
	 ﾠ
Figure	 ﾠ5.	 ﾠsiHoxA1	 ﾠreduces	 ﾠmammary	 ﾠtumor	 ﾠcell	 ﾠproliferation	 ﾠin	 ﾠvivo	 ﾠthrough	 ﾠmodulation	 ﾠof	 ﾠ
p44/42	 ﾠMAPK	 ﾠsignaling.	 ﾠ(A)	 ﾠMicroarray	 ﾠanalysis	 ﾠof	 ﾠMAPK	 ﾠpathway	 ﾠsignature	 ﾠgenes	 ﾠin	 ﾠuntreated	 ﾠ	 ﾠ
	 ﾠ 27	 ﾠ
transgenic	 ﾠC3(1)-ﾭ‐SV40TAg	 ﾠmammary	 ﾠglands	 ﾠ(n	 ﾠ=	 ﾠ3)	 ﾠat	 ﾠprogressive	 ﾠdisease	 ﾠstages.	 ﾠ(B)	 ﾠThe	 ﾠeffect	 ﾠ
of	 ﾠbi-ﾭ‐weekly	 ﾠsiHoxA1	 ﾠinjections	 ﾠon	 ﾠprotein	 ﾠexpression	 ﾠof	 ﾠMAPK	 ﾠcomponents,	 ﾠERK1/2,	 ﾠSRC,	 ﾠIER3,	 ﾠ
KRAS,	 ﾠPCNA	 ﾠand	 ﾠGRB2,	 ﾠin	 ﾠmammary	 ﾠglands	 ﾠof	 ﾠ21-ﾭ‐week	 ﾠold	 ﾠtransgenic	 ﾠanimals	 ﾠ(n	 ﾠ=	 ﾠ3)	 ﾠcompared	 ﾠ
with	 ﾠinjection	 ﾠof	 ﾠnon-ﾭ‐targeting	 ﾠcontrol	 ﾠsiRNA	 ﾠ(siNT)	 ﾠ(n	 ﾠ=	 ﾠ3).	 ﾠ	 ﾠ
 